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Abstract	  
Breast	  cancer	  is	  the	  most	  commonly	  diagnosed	  cancer	  among	  women	  and	  is	  the	  leading	   cause	   of	   cancer	   death	   in	   both	   developing	   and	   developed	   areas.	  Triple-­‐negative	   breast	   cancer,	   one	   of	   the	   subtypes	   of	   breast	   cancer,	   is	   generally	  more	   aggressive	   and	  has	   fewer	   treatment	   options	   compared	  with	   other	   subtypes,	  due	  to	  the	  absence	  of	  drug-­‐targetable	  receptors.	   	  Radiotherapy	   delivers	   ionizing	   radiation	   to	   cancerous	   areas,	   leading	   to	   DNA	  damage	  and	  cell	  death.	  There	  has	  been	  controversy	  about	  the	  molecular	  mechanism	  of	  DNA	  damage	   induced	   by	   ionizing	   radiation.	   According	   to	   conventional	   notions,	  biological	  damage	  by	  ionizing	  radiation	  is	  primarily	  induced	  by	  the	  hydroxyl	  radical	  (OH),	   but	   Lu	   et	   al.,	   using	   femtosecond	   time-­‐resolved	   laser	   spectroscopy,	   have	  discovered	   that	   the	   dissociative	   electron	   transfer	   (DET)	   reaction	   of	   the	  weakly-­‐bound	   prehydrated	   electron	   (e!"#! )	   plays	   an	   important	   role	   in	   causing	  chemical	  bond	  and	  DNA	  strand	  breaks.	  Building	  on	  the	  better	  understanding	  of	  DET	  reaction	  mechanisms	   of	   e!"#! ,	   the	  mechanism	  behind	   the	   radiosensitizing	   effect	   of	  cisplatin	  and	  halopyrimidines	  has	  been	  discovered	  by	  our	  group.	  However,	  cisplatin	  has	  severe	  toxicity,	  and	  the	  DET	  reaction	  efficiency	  of	  halopyrimidines	  is	  low.	   	  	  A	   newly	   discovered	   non-­‐platinum-­‐based	   compound,	   FMD-­‐Br-­‐DAB,	   identified	  through	   the	   femtomedicine	   approach,	   was	   tested	   in	   this	   research	   as	   a	   potential	  
	  	  	   iv	  
radiosensitizer.	   Our	   in	   vitro	   results	   have	   confirmed	   that	   FMD-­‐Br-­‐DAB	   can	   exert	  radiosensitizing	  effects	  on	  treated	  triple-­‐negative	  breast	  cancer	  (MDA-­‐MB-­‐231)	  cells	  when	   combined	   with	   radiation.	   Our	   results	   also	   indicate	   that	   FMD-­‐Br-­‐DAB	   can	  enhance	  DNA	  damage	  in	  a	  dose-­‐dependent	  manner	  when	  combined	  with	  radiation.	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Chapter	  1.	  Introduction	  
	  
 Introduction	  to	  Breast	  Cancer	  1.1
	   Breast	   cancer	   is	   the	   most	   common	   malignancy	   among	   women	   globally,	  accounting	  for	  23%	  of	  total	  cancer	  cases	  in	  females.	  It	   is	  the	  second	  most	  common	  cancer	   in	  both	  sexes.	  Annually,	   for	  every	   ten	  newly	  diagnosed	  cancer	  cases,	  one	   is	  breast	   cancer.	   It	   is	   also	   the	   leading	   cause	   of	   cancer	   death	   among	   females	   and	  accounts	   for	  14%	  of	  total	  cancer	  deaths.	   [1,	  2,	  3,	  4]	   In	  Canada,	  one	   in	  nine	  women	  will	  develop	  breast	  cancer	  in	  her	  lifetime.	  It	  is	  estimated	  that	  in	  2014,	  13.8%	  of	  all	  cancer	   deaths	   in	   Canadian	   women	   were	   caused	   by	   breast	   cancer,	   making	   it	   the	  second	  leading	  cause	  in	  cancer	  deaths	  among	  Canadian	  women	  [5].	   	  The	   diagnosis	   of	   breast	   cancer	   has	   increased	   in	   many	   developed	   countries,	  including	   the	   United	   States	   and	   Canada,	   since	   the	   early	   1980s	   due	   to	   the	   rapid	  growth	  of	  the	  application	  of	  mammographic	  screening	  [1,	  6].	   	  	  	   	  
	  	  	   2	  
1.1.1 Breast	  Cancer	  Subtypes	  
	   Breast	   cancer	   is	   a	   heterogeneous	   disease	   and	   can	   be	   classified	   as	   different	  subtypes	  according	  to	  phenotype	  and	  genotype	  or	  a	  tumor’s	  position,	  stage,	  grade,	  and	   histology.	   The	   distinction	   between	   the	   subtypes	   of	   breast	   cancer	   has	   a	   great	  impact	   on	   prognosis	   and	   survival,	   and	   it	   is	   also	   critical	   to	   making	   appropriate	  treatment	  decisions.	  [7]	   	  According	   to	   tumor	   histology,	   breast	   cancer	   can	   be	   characterized	   by	  microscopic	   organization	   and	   the	   growth	   pattern	   of	   cancer	   cells.	   Most	   breast	  cancers	  are	  derived	  from	  milk	  ducts	  and	  lobules,	  and	  these	  types	  are	  named	  ductal	  carcinomas	  and	  lobular	  carcinomas,	  respectively.	  Based	  on	  the	  distribution	  of	  tumor	  cells,	  breast	  cancer	  can	  also	  be	  classified	  as	  in	  situ	  or	  invasive.	  Ductal	  carcinoma	  in	  situ	  (DCIS)	  is	  a	  type	  of	  pre-­‐cancer	  inside	  of	  the	  ductal	  system	  that	  has	  not	  spread	  to	  nearby	  tissue.	  Lobular	  carcinoma	  in	  situ	  (LCIS)	  rarely	  develops	  into	  invasive	  cancer	  but	   it	  can	  signal	  a	  higher	  risk	  of	  developing	   invasive	  breast	  cancer.	   [8]	  DCIS	   is	   the	  most	   common	   type	   of	   in	   situ	   breast	   cancer,	   accounting	   for	   80-­‐85%	   of	   all	   in	   situ	  tumors,	  while	  lobular	  carcinoma	  in	  situ	  (LCIS)	  accounts	  for	  only	  about	  5%	  [9].	   	  With	   respect	   to	   invasive	  breast	   cancer	   in	  developed	  countries,	   invasive	  ductal	  carcinoma	   (IDC),	   the	  most	   common	   subtype,	   accounts	   for	   about	  70-­‐73%.	   Invasive	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lobular	  carcinoma	  (ILC),	  the	  second	  most	  common	  subtype,	  accounts	  for	  13-­‐16%	  of	  invasive	  breast	  cancers	  in	  developed	  countries	  [10].	  Some	  other	  subtypes	  of	  breast	  cancer	   include	  mucinous,	   comedo,	   inflammatory,	   tubular,	  medullary,	  and	  papillary	  carcinomas	  [11].	   	  Breast	  cancer	  can	  also	  be	  classified	  by	  molecular	  and	  genetic	  markers	  of	  tumors,	  including	   human	   epidermal	   growth	   factor	   receptor	   type	   2	   (HER2),	   progesterone	  receptor	   (PR)	  and	  estrogen	  receptor	   (ER).	  HER2,	   a	  growth	   factor	  receptor	  gene,	   is	  amplified	   in	   25	   to	   30	   percent	   of	   breast	   cancer	   cases,	   called	  HER2+	   breast	   cancer	  [12].	  ER	  status	   is	  also	  a	  very	   important	   factor	   in	  classifying	  breast	  cancer.	  Tumors	  that	  express	  receptors	  for	  estrogen	  are	  estrogen-­‐receptor-­‐positive	  (ER+).	  Estrogens	  can	   pass	   through	   cell	   membranes	   and	   bind	   the	   ERs,	   transforming	   them	   into	  DNA-­‐binding	   transcription	   factors	   that	   stimulate	   estrogen-­‐mediated	   growth	  pathways	   and	   impact	   cellular	   function	   [13].	   A	   cancer	   is	  progesterone-­‐receptor-­‐positive	  (PR+)	  if	  it	  has	  progesterone	  receptors.	  A	  number	  of	  studies	  have	  confirmed	  that	  ER	  expression	  is	  strongly	  correlated	  with	  other	  tumor	  markers,	   for	  example	  PR.	  Studies	  have	  shown	   that	  more	   than	  80%	  of	  ER+	   tumors	  are	  PR+	   and	   greater	   than	  90%	  of	   ER-­‐	   tumors	   are	   also	  PR-­‐	   [15].	   Tumors	   that	   lack	  expression	  of	  ER,	  PR,	  and	  HER2	  are	  defined	  as	  triple-­‐negative	  breast	  cancers.	  About	  15	  to	  20%	  of	  breast	  cancer	  cases	  are	  triple-­‐negative	  [14].	  Therefore,	  with	  the	  help	  of	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complementary	  DNA	   (cDNA)	  microarray	   technology,	   breast	   cancer	   is	   divided	   into	  five	   distinct	   subtypes:	   luminal	   A,	   luminal	   B,	   HER-­‐2	   overexpressed,	   basal-­‐like,	   and	  normal-­‐like	   [16].	   Luminal	  A	   and	   luminal	   B	   subtypes	   are	   both	  ER+	   and	   low-­‐grade,	  but	  luminal	  A	  is	  HER2-­‐	  and	  has	  a	  better	  prognosis,	  whereas	  luminal	  B	  is	  HER2+	  and	  grows	  more	  quickly.	  Basal-­‐like	  tumors	  exhibit	  a	  high	  expression	  of	  the	  characteristic	  genes	  of	  basal	   epithelial	   cells.	  Most	  basal-­‐like	   tumors	  are	   triple-­‐negative,	  meaning	  they	  are	  ER-­‐,	  PR-­‐	  and	  HER2-­‐.	  HER2	  overexpressed	  breast	  tumors	  have	  extra	  copies	  of	   the	   HER-­‐2	   gene.	   About	   six	   to	   ten	   percent	   of	   breast	   cancers	   are	   normal-­‐like	   or	  unidentified.	   These	   tumors	   are	   usually	   small	   and	   tend	   to	   have	   a	   good	   prognosis.	  [18,19]	  	  
1.1.2 Breast	  Cancer	  Screening	  and	  Diagnostic	  Approaches	  
	   Breast	   cancer	   screening	   can	   help	   diagnose	   cancer	   at	   an	   early	   stage	   and	   avert	  deaths.	  Common	  screening	  tests	  include	  Mammography,	  clinical	  breast	  exam	  (CBE),	  breast	  self-­‐examination	  (BSE),	  ultrasound,	  and	  magnetic	  resonance	   imaging	  (MRI).	  Mammography,	   a	   common	   screening	   method,	   is	   a	   type	   of	   radiography.	   The	  widespread	  use	  of	  screening	  mammography	   in	  developed	  countries	  has	   lead	  to	  an	  increased	   diagnosis	   of	   breast	   cancer	   and	   has	   significantly	   reduced	   breast	   cancer	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mortality	   in	  women	   between	   50	   to	   70	   years	   of	   age	   [20,	   21].	   A	  meta-­‐analysis	   has	  shown	   14%	   breast	   cancer	   death	   reduction	   for	   women	   in	   their	   50s	   and	   32%	   for	  those	  in	  their	  60s	  [22].	  However,	  mammography	  is	  not	  very	  useful	  in	  finding	  breast	  tumors	  in	  younger	  women	  who	  tend	  to	  have	  dense	  breasts.	  It	  has	  been	  concluded	  by	  the	   U.S.	   Preventive	   Services	   Task	   Force	   (USPSTF)	   that	   the	   benefits	   of	   regular	  mammography	   increase,	  and	   the	  harm	   from	   it	  decreases	  when	  age	   increases	   [23].	  The	  recommended	  age	  at	  which	  screening	  should	  begin	  varies	  across	  counties.	  For	  example,	  in	  Canada	  women	  age	  50	  to	  69	  are	  recommended	  to	  have	  a	  mammogram	  every	   two	   years.	   For	   many	   years,	   doing	   regular	   BSE	   has	   been	   suggested.	   It	   is	  believed	   that	   women	   who	   practice	   BSE	   regularly	   are	   more	   likely	   to	   find	  abnormalities	   earlier,	   leading	   to	   earlier	   treatment	   and	   therefore	   higher	   survival	  rates	   [24].	  However,	  according	   to	  a	  systematic	   review	  by	   the	  USPSTF	   in	  2009,	   the	  effectiveness	  of	  CBE	  and	  BSE	  in	  decreasing	  breast	  cancer	  mortality	  is	  controversial.	  No	  big	  differences	  were	  found	  in	  studies	  using	  mammography	  alone	  versus	  studies	  using	  mammography	  and	  CBE	  [23].	  MRI,	  which	  is	  less	  commonly	  used,	  has	  very	  high	  negative	  predictive	  values	  and	  can	  be	  used	  to	  screen	  patients	  with	  radiographically	  dense	   breasts.	   It	   can	   also	   diagnose	   common	   benign	   conditions	   other	   than	   cancer.	  However,	   MRI	   is	   more	   expensive	   and	   may	   have	   more	   false	   positives	   than	  mammography	   [25,26].	   Breast	   ultrasound,	   a	   diagnostic	   aid	   to	   mammography,	   is	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frequently	  used	  as	  a	  targeted	  diagnostic	  examination	  focusing	  on	  a	  specific	  area.	  It	  may	  be	  used	  in	  pregnant	  women	  and	  women	  younger	  than	  25	  years	  old,	  but	  it	  has	  higher	  rates	  of	  false-­‐positive	  examination	  results	  than	  mammography	  [27].	   	  If	  suspicious	  areas	  are	  found	  by	  screening,	  CBE	  or	  BSE,	  additional	  imaging	  and	  biopsy	   may	   be	   recommended.	   Current	   biopsy	   techniques	   include	   fine-­‐needle	  aspiration	   biopsy	   (FNAB),	   stereotactic	   core	   biopsy,	   image-­‐guided	   core	   biopsy,	  non-­‐image-­‐guided	  core	  biopsy,	  and	  excisional	  biopsy	  [28].	  The	  types	  of	  biopsy	  vary	  by	   the	   invasiveness	   level	   and	   amount	   of	   tissue	   acquired.	   FNAB,	   using	   a	   smaller	  needle,	   is	   less	   invasive	   and	   is	   less	   likely	   to	   cause	   hematoma	   than	   core	   biopsy.	  However,	   due	   to	   the	   smaller	   needle	   size	   of	   FNAB,	   it	   may	   obtain	   an	   insufficient	  sample	  and	  therefore	  is	   less	  reliable	  than	  core	  biopsy	  [29].	  It	  has	  been	  shown	  that	  the	  use	  of	  stereotactic	  core	  needle	  biopsies	  shortens	  the	  time	  between	  abnormality	  detection	  by	  mammography	  and	  pathologic	  diagnosis	  [30].	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1.1.3 Treatments	  
	   The	  treatment	  of	  most	  breast	  cancers	  is	  multidisciplinary.	  They	  can	  be	  treated	  by	  surgery,	   radiotherapy,	  and	  chemotherapy.	  Some	  certain	  cases	  of	  breast	  cancers	  can	   be	   treated	   by	   hormone	   therapy	   and	   targeted	   therapy	   depending	   on	   hormone	  receptor	  status,	  overexpression	  of	  some	  genes,	  and	  patient	  menopausal	  status	  [31].	   	   	  	  
Surgery	  Surgery,	   a	   primary	   treatment	  method	   for	   breast	   cancer,	   is	   aim	   to	   remove	   the	  tumor	  and	  metastases	  in	  regional	  lymphatic	  tissues.	   	  Breast-­‐conserving	  surgery,	   including	   lumpectomy,	  quadrantectomy	  and	  partial	  mastectomy,	  is	  preferred	  when	  a	  tumor	  is	  confined	  to	  one	  area.	  Lumpectomy	  is	  the	  removal	  of	   a	   small	  part	  of	   the	  breast,	   including	   the	  breast	   tumor	  and	   some	  of	   the	  surrounding	   tissues.	  Quadrantectomy	   is	   the	   removal	  of	   around	  one	  quarter	  of	   the	  breast.	   Randomized	   trials	   have	   shown	   that	   radiotherapy	   following	  breast-­‐conserving	   surgery	   decreases	   local	   recurrence	   and	   is	   preferred	   for	   most	  women	  with	  early	  breast	  cancer,	  but	  it	  is	  not	  recommended	  for	  women	  at	  high	  risk	  of	  local	  recurrence	  [32,	  33].	   	  A	  radical	  mastectomy	  is	  recommended	  when	  the	  tumor	  is	  too	  extensive	  or	  there	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is	  a	  clinically	  positive	  axilla.	  It	  removes	  all	  of	  the	  breast	  tissue	  and	  the	  axillary	  lymph	  nodes	   [33].	   Most	   often,	   breast	   reconstruction	   is	   performed	   at	   the	   time	   of	   the	  mastectomy.	   	  	  
Radiotherapy	  Radiotherapy	   is	   a	   treatment	   using	   ionizing	   radiation	   to	   control	   or	   kill	   cancer	  cells.	  The	  mechanism	  of	  radiotherapy	  is	  to	  destroy	  cells	  in	  the	  area	  being	  treated	  by	  damaging	  the	  DNA	  of	  the	  cells,	  making	  them	  unable	  to	  grow	  and	  divide.	   	  Typically,	   women	   with	   early	   stage	   breast	   cancer	   who	   have	   undergone	  breast-­‐conserving	  surgery	  are	  treated	  with	  radiotherapy	  to	  lower	  their	  risk	  of	  local	  chest	   wall	   and	   regional	   lymph	   node	   recurrence.	   A	   review	   of	   ten	   randomized	  controlled	  trials	  showed	  that	  breast-­‐conserving	  surgery	  with	  radiation	  significantly	  reduced	   the	   five-­‐year	   local	   recurrence	   rate	   and	   appeared	   to	   decrease	   the	   15-­‐year	  mortality	  risk	  [34].	   	  	  
Chemotherapy	   	  Chemotherapy	  can	  be	  administered	  prior	  to	  cancer	  surgery	  as	  neoadjuvant	  (or	  preoperative)	   chemotherapy	   to	   shrink	   tumors.	   Patients	   with	   inoperable	   breast	  cancer	   for	   surgery	   are	   considered	   for	   neoadjuvant	   chemotherapy	   because	   it	   can	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shrink	  tumors	  sufficiently	  to	  make	  resection	  possible.	  Patients	  with	  operable	  breast	  cancer	  but	  who	  are	  poor	  candidates	  for	  breast-­‐conserving	  surgery	  because	  of	  large	  tumor	   size	   may	   also	   be	   offered	   neoadjuvant	   chemotherapy	   to	   facilitate	   less	  disfiguring	  surgery	  [35].	  Another	  benefit	  of	  neoadjuvant	  chemotherapy	  is	  that	  initial	  responsiveness	   can	   be	   assessed	   by	   measuring	   tumor	   sizes,	   providing	   prognostic	  information.	   Thus,	   ineffective	   chemotherapy	   can	   be	   stopped,	   avoiding	   further	  cytotoxicity	   [36].	   However,	   there	   may	   be	   some	   unresolved	   concerns	   about	  neoadjuvant	  chemotherapy.	  One	   issue	  concerns	   the	   timing	  of	   sentinel	   lymph	  node	  biopsies	   (SLNBs),	   a	   preferred	   method	   for	   evaluating	   axillary	   lymph	   nodes.	  Chemotherapeutic	  drugs	  may	  induce	  lymphatic	  damage	  and	  may	  interfere	  with	  this	  procedure.	   It	   has	   been	   reported	   that	   SLNB	   following	   neoadjuvant	   chemotherapy	  may	   result	   in	   higher	   rates	   of	   false-­‐negatives,	   and	   this	   may	   lead	   to	   the	  undertreatment	  of	  a	  subset	  of	  patients	  [37].	  However,	  if	  SLNB	  is	  performed	  prior	  to	  neoadjuvant	   chemotherapy,	   patients	   need	   to	   undergo	   another	   operation,	   which	  would	  otherwise	  be	  performed	  during	  a	  single	  surgery.	  Adjuvant	  chemotherapy	  is	  also	  a	  general	  treatment	  for	  breast	  cancer	  patients.	  It	  is	  administered	  by	  applying	  cytotoxic	  chemotherapy	  or	  ablative	  endocrine	  therapy	  after	   primary	   surgery.	   During	   the	   past	   few	   decades,	   adjuvant	   chemotherapy	   has	  undergone	  many	   significant	   changes.	   Forty	   years	   ago,	   only	   breast	   cancer	   patients	  
	  	  	   10	  
with	  positive	  nodes	  received	  adjuvant	  chemotherapy.	  It	  was	  not	  until	  the	  1970s	  that	  women	   with	   node-­‐negative	   breast	   cancer	   could	   benefit	   from	   adjuvant	  chemotherapy	  [41].	   In	   the	  1990s,	  anthracyclines,	  doxorubicin	  and	  epirubicin	  were	  first	   introduced.	   Nowadays,	   common	   chemotherapy	   agents	   used	   in	   the	   adjuvant	  setting	  are	  cyclophosphamide,	  methotrexate,	  5-­‐fluorouracil,	  doxorubicin,	  epirubicin,	  paclitaxel,	  and	  docetaxel	  [41].	  Cyclophosphamide	  is	  an	  alkylating	  agent	  that	  adds	  an	  alkyl	  group	  to	  the	  guanine	  base	  of	  DNA,	  and	  therefore	  causes	  DNA	  cross-­‐linking	  and	  interferes	  with	  DNA	  replication	  and	  cell	  division.	  Methotrexate	  is	  an	  antimetabolite	  and	  antifolate	  drug	  that	  blocks	  dihydrofolate	  reductase	  (DHFR),	  which	  is	  an	  enzyme	  participating	   in	   the	   conversion	   of	   folic	   acid	   to	   tetrahydrofolic	   acid,	   and	   therefore	  inhibits	   the	  synthesis	  of	  DNA,	  RNA,	   thymidylates,	  and	  proteins	  [38].	  Another	  drug,	  5-­‐fluorouracil	   is	  a	  uracil	  analog	  with	  a	  hydrogen	  atom	  at	  the	  C-­‐5	  position	  replaced	  by	  a	  fluorine	  atom.	  It	  is	  converted	  to	  several	  active	  metabolites	  intracellularly,	  and	  these	   metabolites	   disrupt	   RNA	   synthesis	   and	   inhibit	   the	   action	   of	   thymidylate	  synthase,	   and	   therefore	   slow	  or	   stop	  cell	   growth	   [39].	  Doxorubicin	  and	  epirubicin	  are	  both	  anthracyclines;	  epirubicin	  is	  an	  analogue	  of	  doxorubicin.	  Doxorubicin	  binds	  directly	   to	   the	   base	   pairs	   of	   the	  DNA	   or	   RNA	   and	   inhibits	   the	   replication	   of	   cells.	  Similar	   to	   Doxorubicin,	   epirubicin	   works	   by	   intercalating	   DNA	   strands,	   inhibiting	  DNA	  and	  RNA	  synthesis.	  It	  can	  also	  form	  a	  cleavable	  complex	  with	  topoisomerase	  II	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and	  DNA,	   leading	   to	   inhibition	   of	   topoisomerase	   II	   and	  preventing	   the	   relaxing	   of	  supercoiled	   DNA,	   and	   finally	   blocking	   the	   DNA	   synthesis	   pathway.	   Paclitaxel	   and	  docetaxel	   are	   both	   taxanes.	   Paclitaxel	   is	   an	   antimicrotubule	   agent	   that	   stabilizes	  microtubule	  polymer,	  promoting	  the	  assembly	  of	  microtubules	  and	  protecting	  them	  from	  disassembly.	   It	   therefore	   inhibits	  mitotic	   spindle	   function	  and	  blocks	  mitosis	  and	   cell	   division.	   Docetaxel	   is	   a	   semisynthetic	   taxane	   and	   shares	   a	   similar	  mechanism	   to	   paclitaxel’s	   but	   docetaxel	   is	   slightly	   more	   water-­‐soluble	   than	  paclitaxel	  [39].	  For	   adjuvant	   chemotherapy,	   combination	   therapy	   is	   more	   effective	   than	  single-­‐drug	   therapy.	   The	   combination	   of	   cyclophosphamide,	   methotrexate,	   and	  fluorouracil	   (CMF)	  was	   the	   first	   polychemotherapy	   regimen,	   and	   it	   showed	  better	  disease-­‐free	  and	  overall	  survival	  than	  single	  agent	  treatment	  in	  early	  breast	  cancer.	  The	  combination	  of	  Fluorouracil,	  anthracyclines,	  and	  cyclophosphamide	  (FA[E]C),	  a	  regimen	   in	   which	   the	   methotrexate	   of	   CMF	   is	   replaced	   with	   doxorubicin	   or	  epirubicin,	  has	  been	  tested	  in	  many	  trials	  and	  is	  used	  in	  routine	  practice	  [41,	  42].	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Hormonal	  Therapy	  It	   was	   first	   recognized	   by	   Beatson	   in	   1896	   that	   some	   breast	   cancer	   patients	  responded	   favorably	   to	   oophorectomy,	  which	   is	   removal	   of	   ovaries.	   This	  was	   the	  first	  hint	  that	  some	  breast	  tumors	  are	  dependent	  upon	  hormone	  for	  growth	  and	  led	  to	  the	  discovery	  of	  hormonal	  therapy	  [43].	   	  Hormonal	   therapy	   can	   be	   used	   to	   treat	   hormone	   receptor-­‐positive	   tumors	   by	  lowering	  the	  amount	  of	  hormone	  or	  by	  blocking	  the	  stimulating	  action	  of	  hormone	  on	   breast	   cancer	   cells.	   Typical	   hormonal	   treatments	   include	   selective	   estrogen	  response	   modifiers	   (SERMs),	   aromatase	   inhibitors,	   gonadotropin-­‐releasing	  hormone	  (GnRH)	  agonists.	  [44]	  SERMs	   are	   compounds	   that	   can	   exert	   selective	   estrogen	   antagonistic	   or	  estrogen	   agonistic	   effects,	   depending	   on	   various	   estrogen	   target	   tissues.	   They	   can	  block	   the	   action	   of	   estrogen	   in	   certain	   tissues	   while	   mimicking	   the	   action	   of	  estrogen	   in	  other	   tissues.	  Tamoxifen	  was	   the	   first	  SERM	  to	  be	   investigated.	   It	  was	  first	  introduced	  to	  treat	  advanced	  breast	  cancer	  of	  postmenopausal	  women	  but	  was	  later	   approved	   to	   treat	   ER+	   breast	   cancer	   of	   both	   premenopausal	   and	  postmenopausal	  women.	  It	  is	  still	  the	  most	  commonly	  used	  SERM	  [41].	  Tamoxifen	  is	  a	   competitive	   antagonist	   to	   estrogen	   at	   the	   level	   of	   estrogen	   receptor	   in	   breast	  tissues	  while	  acting	  as	  an	  agonist	   in	  other	  tissues,	   for	  example	  bone	  and	  uterus.	   It	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exhibits	  antagonistic	  effects	  by	  competitively	  binding	  to	  the	  ER	  sites	  on	  breast	  cell	  membranes	   and	   inhibiting	   the	   expression	   of	   estrogen-­‐regulated	   genes	   that	   may	  promote	   cellular	   proliferation	   and	   tumor	   growth	   [44].	   It	   may	   also	   decrease	   the	  production	  of	  insulin-­‐derived	  growth	  factors	  in	  breast	  tissues,	  while	  increasing	  the	  production	   of	   tumor-­‐suppressive	   growth	   factors,	   and	   as	   a	   consequence,	   inhibit	  tumor	  growth	  [46].	  However,	  it	  was	  found	  that	  tamoxifen	  exerts	  estrogen	  agonistic	  effect	  on	  the	  endometrium,	  and	  it	  leads	  to	  increase	  in	  endometrial	  cancer	  in	  women	  taking	   tamoxifen	   for	   five	   years	   [47].	   In	   addition	   to	   the	   therapeutic	   effect	   of	  tamoxifen,	   on	   existing	   tumors,	   studies	   have	   revealed	   that	   it	   can	   be	   used	   for	   the	  prevention	   of	   breast	   cancer	   as	   it	   reduces	   the	   risk	   of	   estrogen	   receptor-­‐positive	  tumors	  and	  osteoporotic	  fractures	  in	  women	  at	  high	  risk	  of	  breast	  cancer	  [48].	   	  Aromatase	  inhibitors	  work	  by	  blocking	  aromatase,	  an	  enzyme	  that	  converts	  the	  body’s	  androgens	  into	  estrogens.	  Postmenopausal	  women	  get	  most	  of	  their	  estrogen	  from	  this	  conversion.	  Therefore,	  aromatase	  inhibitor	  treatment	  is	  considered	  in	  all	  postmenopausal	   women	   with	   hormone	   receptor	   positive	   breast	   cancer	   but	   not	  premenopausal	  women,	  because	  before	  reaching	  menopause,	  women	  produce	  most	  of	   their	   estrogen	   in	   the	   ovaries	   and	   aromatase	   inhibitors	   cannot	   stop	   the	   ovaries	  from	   making	   estrogen.	   Commonly	   used	   aromatase	   inhibitors	   are	   anastrozole,	  exemestane,	   and	   letrozole.	   Several	   studies	   have	   compared	   aromatase	   inhibitors	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with	   tamoxifen	   in	   treating	   postmenopausal	   women	   with	   early-­‐stage,	  hormone-­‐receptor	   positive	   breast	   cancer	   [49].	   It	   has	   been	   suggested	   that	  anastrozole	   is	   better	   in	   terms	   of	   time	   to	   progression	   (TTP)	   for	   patients	   with	  hormone	   receptor-­‐positive	   tumors	   [50,	   51].	   A	   study	   comparing	   letrozole	   with	  tamoxifen	  has	  also	  shown	  that	  letrozole	  is	  significantly	  superior	  to	  tamoxifen	  in	  TTP,	  time	   to	   treatment	   failure	   (TTF),	  objective	  response	  rate	   (ORR)	  and	  clinical	  benefit	  rate	  [52].	  Comparison	  between	  exemestane	  and	  tamoxifen	  has	  also	  shown	  a	  better	  overall	  response	  rate	  for	  exemestane	  than	  tamoxifen	  [53].	   	  	  
Targeted	  Therapy	  Targeted	  therapies	  interfere	  with	  specific	  molecular	  targets	  that	  are	  involved	  in	  the	   growth,	   progression	   and	   spread	  of	   cancer.	   Commonly	  used	   targeted	   therapies	  include	   tyrosine	   kinase	   inhibitors,	   inhibitors	   of	   intracellular	   signaling	   pathways,	  angiogenesis	  inhibitors	  and	  agents	  targeting	  DNA	  repair	  [54].	   	  
HER-­‐2	   is	   a	   proto-­‐oncogene	   that	   encodes	   a	   transmembrane	   tyrosine	   kinase	  receptor	   protein.	   HER-­‐2	   is	   amplified	   in	   20-­‐30%	   of	   human	   breast	   cancers.	  Overexpression	  of	  HER-­‐2	  is	  related	  to	  rapid	  proliferation	  and	  growth	  of	  cancer	  cells,	  and	   these	   tumors	   are	  more	   aggressive	   and	   resistant	   to	   chemotherapy,	   leading	   to	  poor	  prognosis,	  but	  this	  also	  makes	  it	  the	  most	  successful	  target	  [55].	  A	  number	  of	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drugs	   have	   been	   developed	   to	   target	   HER-­‐2	   protein,	   including	   trastuzumab,	  pertuzumab,	   trastuzumab	   emtansine,	   and	   lapatinib.	   Trastuzumab,	   a	   monoclonal	  antibody	   that	  blocks	   the	  effects	  of	  HER-­‐2	  protein,	  may	  be	  used	   to	   treat	  both	  early	  stage	  and	  late	  stage	  breast	  cancer;	  it	  has	  demonstrated	  benefit	  both	  as	  a	  single	  agent	  and	  when	  used	  in	  combination	  with	  chemotherapy	  in	  treating	  HER-­‐2	  positive	  breast	  cancer.	   Pertuzumab	   is	   also	   a	   monoclonal	   antibody	   and	   it	   can	   be	   given	   with	  trastuzumab	   and	   chemotherapy.	   Lapatinib,	   a	   dual	   tyrosine	   kinase	   inhibitor	   that	  inhibits	   both	   HER-­‐2	   and	   EGFR	   pathways,	   can	   be	   used	   to	   treat	   patients	   with	  advanced	  or	  metastatic	  HER-­‐2	  positive	  breast	  cancers.	  [53,	  55]	  Angiogenesis	  is	  required	  for	  invasive	  tumor	  growth	  and	  metastasis,	  making	  it	  a	  potential	  target	  to	  inhibit	  tumor	  growth.	  Vascular	  endothelial	  growth	  factors	  (VEGFs)	  are	   among	   the	   most	   prominent	   factors	   leading	   to	   pathological	   angiogenesis.	  Bevacizumab,	   the	   first	   agent	   targeting	   angiogenesis	   in	   breast	   cancer,	   is	   a	  monoclonal	  antibody	  directed	  against	  VEGF-­‐A,	  one	  of	  the	  VEGFs	  [56].	   	  Some	   targeted	   agents	   can	   be	   used	   along	   with	   hormone	   therapeutic	   drugs	   to	  improve	  treatment	  outcomes,	  for	  example	  palbociclib	  and	  everolimus.	  Palbociclib	  is	  a	   selective	   inhibitor	   of	   cyclin-­‐dependent	   kinase	   4	   (CDK4)	   and	   CDK6.	   By	   blocking	  these	  proteins,	  palbociclib	  helps	  stop	  cell	  proliferation	  and	  slow	  cancer	  growth	  [57].	  Everolimus	  is	  an	  inhibitor	  of	  mammalian	  target	  of	  rapamycin	  (mTOR),	  a	  protein	  that	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promoters	   cell	   growth	   and	   division.	   It	   has	   been	   approved	   for	   postmenopausal	  patients	   with	   ER+	   advanced	   or	   metastatic	   breast	   cancer	   that	   is	   resistant	   to	  aromatase	  inhibitors	  [58].	   	   	  	  
1.1.4 Triple-­‐negative	  breast	  cancer	  
	   It	  has	  been	  estimated	  that	  about	  15	  to	  20%	  of	  breast	  cancers	  are	  triple-­‐negative.	  Unlike	   other	   subtypes	   of	   breast	   cancer,	   triple-­‐negative	   breast	   cancer	   cannot	   be	  treated	   with	   hormonal	   therapies	   and	   therapies	   targeting	   HER2,	   and	   there	   is	   no	  single	  targeted	  therapy	  that	  is	  efficacious	  treating	  it	  [16,	  58].	  Triple-­‐negative	  breast	  cancer	  tumors	  tend	  to	  be	  larger	  in	  size	  and	  higher	  in	  grade	  and	  are	  generally	  more	  aggressive,	  with	  a	  high	  metastatic	  rate.	  Despite	  higher	  rates	  of	  clinical	  response	  to	  neoadjuvant	   chemotherapy,	   no	   conventional	   therapy	   has	   been	   developed	   for	  triple-­‐negative	   breast	   cancer.	   The	   lack	   of	   treatment	   options	   and	   the	   intrinsic	  aggressiveness	   of	   triple-­‐negative	   breast	   cancer	   lead	   to	   poor	   prognosis	   and	  treatment	   outcomes	   [60].	   Therefore,	   it	   is	   imperative	   to	   develop	   an	   effective	  therapeutic	  approach.	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 Radiotherapy	  1.2
	  	   Types	  of	   radiation	  used	   for	  cancer	   treatment	   include	  photon	  radiation	  (X-­‐rays	  and	  ϒ-­‐rays)	  and	  particle	  radiation	  (protons,	  neutrons,	  boron,	  carbon	  and	  neon	  ions).	  According	   to	   the	   delivery	   method,	   radiotherapy	   can	   be	   classified	   as	   external	  radiotherapy,	  internal	  radiotherapy,	  and	  systemic	  radioisotope	  therapy.	   	  	   External	  radiotherapy	  (or	  teletherapy),	  the	  most	  common	  form	  of	  radiotherapy,	  delivers	   a	   beam	   of	   ionizing	   radiation	   pointed	   at	   cancerous	   areas	   by	   a	   machine	  outside	   of	   the	   body.	   Recent	   advances	   in	   external	   radiotherapy	   include	  three-­‐dimensional	   conformal	   radiotherapy	   (3D-­‐CRT),	   intensity-­‐modulated	  radiotherapy	   (IMRT),	   image-­‐guided	   radiotherapy	   (IGRT),	   and	   stereotactic	   body	  radiotherapy	   (SBRT)	   [61].	   3D-­‐CRT	   delivers	   a	   precisely	   shaped	   radiation	   beam	  conforming	  to	  the	  shape	  of	  the	  tumor,	  and	  therefore	  reduces	  toxicity	  to	  surrounding	  normal	   tissues	   [62].	   IMRT	   is	   an	   advanced	   form	   of	   3D-­‐CRT	   that	   allows	   radiation	  doses	   to	   conform	   more	   precisely	   to	   tumor	   shapes	   while	   minimizing	   the	   dose	   to	  normal	   tissues	   by	   modulating	   the	   intensity	   of	   each	   segment	   of	   radiation	   beam	  during	   treatment	   sessions	   [63].	   Studies	   have	   found	   that	   IMRT	   for	   treatment	   of	  breast	  cancer	  may	  be	  able	  to	  reduce	  doses	  delivered	  to	  the	  heart	  and	  lungs	  due	  to	  the	   improved	   target	   coverage	   [64].	   IGRT	   incorporates	   contemporary	   imaging	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techniques,	   such	   as	   CT	   and	   MRI,	   to	   frequently	   confirm	   the	   tumor	   and	   patient	  position	  during	  treatment,	  and	  therefore	  increase	  the	  accuracy	  of	  target	  localization	  and	  reduce	  damage	  to	  health	  tissue	  [61].	  SBRT	  gives	  radiation	  from	  many	  different	  directions	  to	  target	  tumor	  areas	  and	  thus	  tumors	  receive	  a	  higher	  dose	  of	  radiation	  than	  normal	  tissue	  [65].	   	   	  Internal	   radiotherapy	   (brachytherapy)	   delivers	   radiation	   from	   a	   radiation	  source	   placed	   in	   the	   body	   near	   cancerous	   tissue.	   For	   example,	   balloon	   catheters	  filled	   with	   radioisotopes	   can	   be	   used	   to	   limit	   local	   recurrence	   after	   the	   primary	  treatment	  of	  breast	  cancer	  [66].	  In	   systemic	   radiotherapy,	   radioactive	   substances,	   for	   example	   iodine-­‐131	   and	  strontium-­‐89,	   are	   given	   orally	   or	   by	   injection.	   The	   radioactive	   substance	   can	   be	  attached	   to	   a	   monoclonal	   antibody	   that	   targets	   cancer	   cells	   to	   improve	   accuracy	  [61].	   	  	  
1.2.1 Target	  of	  radiotherapy	  
	   The	  principle	  target	  of	  radiotherapy	  is	  the	  DNA	  of	  cancerous	  cells.	  DNA	  damage	  induced	  by	  radiation	  can	  be	  caused	  by	  direct	  interaction	  or	  indirect	  interaction.	  For	  the	  direct	  interaction,	  ionizing	  energy	  is	  directly	  deposited	  into	  DNA	  molecules,	  and	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the	  DNA	  molecules	  are	  directly	  ionized	  or	  excited,	   leading	  to	  DNA	  damage.	  For	  the	  indirect	   interaction,	   ionizing	   radiation	   energy	   is	   deposited	   in	  water	   first,	   forming	  free	  radicals,	  and	  the	  radicals	  react	  with	  DNA	  molecules,	  causing	  damage.	  With	  high	  linear	   energy	   transfer	   (LET)	   radiation,	   for	   example	   particle	   radiation,	   the	   direct	  ionizing	  effect	  dominates,	  whereas	  under	  low	  LET	  radiation,	  for	  example	  X-­‐ray	  and	  ϒ-­‐ray,	  the	  indirect	  effect	  dominates.	   	  	  
1.2.2 Mechanism	  of	  radiotherapy	  
	   Experiments	  have	  shown	  that	  the	  yields	  of	  DNA	  single-­‐strand	  breaks	  (SSBs)	  and	  double-­‐strand	  breaks	  (DSBs)	  are	   three	  orders	  of	  magnitude	  higher	   in	   the	  aqueous	  DNA	  samples	  than	  those	   in	  the	  dry	  condition	  at	  25°C,	   indicating	  water	  plays	  a	  key	  role	  for	  biological	  effect	  caused	  by	  ionizing	  radiation	  [67].	  Therefore,	  how	  radiolysis	  of	   water	   leads	   to	   DNA	   damage	   is	   the	   key	   to	   understanding	   the	   mechanism	   of	  radiation.	   It	   is	   well	   know	   that	   the	   major	   products	   of	   water	   radiolysis	   are	   OH	  (hydroxyl	   radical)	   and	   e!"#! 	   (hydrated	   electron),	   but	   the	   e!"#! 	   is	   inefficient	   at	  introducing	  biological	  damage	  since	  it	  is	  trapped	  in	  a	  deep	  potential	  well	  [68].	  Some	  other	  experiments	  with	  bacterial	  and	  mammalian	  cell	  systems	  have	  also	  shown	  that	  one	  third	  of	  biological	  effect	  is	  induced	  by	  direct	  interaction	  between	  radiation	  and	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DNA,	   whereas	   two	   thirds	   of	   biological	   effect	   is	   induced	   by	   OH.	   However,	   this	  conclusion	  is	  contradictory	  to	  the	  fact	  that	  aqueous	  condition	  enhances	  three	  orders	  of	   magnitude	   higher	   DNA	   damage	   than	   dry	   condition,	   and	   also,	   it	   has	   been	  suggested	   that	   DNA	   damage	   caused	   by	   OH	   alone	   can	   be	   repaired	   efficiently	   and	  hence	  the	  damage	  is	  inconsequential	  and	  ineffective	  in	  cell	  killing	  [69,	  70].	   	  By	  direct	  observation	  of	  the	  transition	  states	  of	  the	  dissociative	  election	  transfer	  (DET)	   reactions	   of	   e!"#! 	   (prehydrated	   election),	   the	   precursor	   to	   e!"#! ,	   using	   the	  femtosecond	  time-­‐resolved	  laser	  spectroscopy	  (fs-­‐TRLS),	  our	  group	  has	  shown	  that	  the	  weakly-­‐bound	   e!"#!   plays	  a	  key	   role	   in	   causing	  damage	   to	  aqueous	  DNA	  under	  ionizing	   radiation,	   and	   our	   findings	   unravel	   the	   longstanding	  mystery	   about	   how	  water	   enhances	   DNA	   damage	   under	   ionizing	   radiation.	   Indeed,	   it	   is	   e!"#! 	   not	   OH	  that	   cause	  biological	  damage	   to	  DNA	  under	   ionizing	  radiation	   [71-­‐74].	  Our	  results	  showed	   that	   cytosine	   and	   especially	   adenine	   can	   effectively	   trap	   an	   e!"#! 	   to	   form	  stable	  anions,	  whereas	  thymidine	  and	  especially	  guanine	  are	  vulnerable	  to	  DETs	  of	  e!"#! ,	   which	   leads	   to	   DNA	   bond	   breaks	   [72]	   Our	   group	   has	   also	   found	   that	   the	  reductive	   DNA	   damage	   induced	   by	   a	   e!"#! ,	   is	   twice	   the	   yield	   of	   oxidative	   DNA	  damage	  induced	  by	  a	  OH	  [74].	  These	  findings	  have	  significance	  for	  understanding	  of	  the	   mechanism	   of	   radiolysis	   of	   water	   and	   the	   role	   of	   water	   in	   biological	   effect	  induced	  by	  ionizing	  radiation.	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1.2.3 Radiosensitizer	  
	   The	  most	  common	  ionizing	  radiation	  sources	  used	  in	  radiotherapy	  are	  low	  LET	  sources	   such	   as	   X-­‐rays	   and	   γ-­‐rays,	   and	   there	   are	   limitations	   in	   doses	   and	  effectiveness	   that	   cause	   failure	   in	   treatment.	   A	   radiosensitizer	   is	   a	   drug	   that	   can	  sensitize	   tumor	   cells	   to	   radiation	   and	   therefore	   enhance	   tumor	   cell	   killing	   while	  having	   less	   effect	   on	   normal	   tissues.	   Tumor	   cells	   have	   different	   physiological	  characteristics	   as	   normal	   tissues;	   radiosensitizers	   can	   target	   these	   properties	   and	  therefore	  enhance	  radiosensitivity	  of	  tumor	  cells.	  [76]	  Cisplatin	  is	  currently	  one	  of	  the	  most	  widely	  used	  chemotherapeutic	  drugs	  and	  has	   shown	   clinical	   activity	   against	   a	   wide	   variety	   of	   solid	   tumors	   [78,	   79].	   Also,	  Combination	   of	   cisplatin	   with	   radiotherapy	   has	   been	   shown	   to	   enhance	   DNA	  damage	  and	  is	  a	  novel	  cancer	  treatment;	  the	  radiosensitizing	  effect	  of	  cisplatin	  has	  also	  been	  demonstrated	   in	  many	  studies	   [80-­‐82].	  By	  using	   fs-­‐TRLS,	  we	   found	   that	  cisplatin	   is	  very	  reactive	   for	   the	  DET	  reaction	  with	   e!"#! 	   produced	  by	  radiolysis	  of	  water,	   and	   this	  process	  unravels	   the	  mechanism	  of	   its	   radiosensitizing	  effect	   [83].	  The	  reaction	  mechanism	  can	  be	  described	  as:	  e!"#!   +   Pt NH! !Cl! → Pt NH! !Cl! ∗! → Cl!   +   Pt NH! !Cl 
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e!"#!   +   Pt NH! !Cl → Pt NH! !Cl ∗! → Cl!   +   Pt NH! ! The	   Pt NH! !Cl	  and	   Pt NH! !	  radicals	  formed	  in	  this	  process	  can	  induce	  DNA	  strand	  breaks	  effectively.	  The	  radiosensitizing	  effects	  of	  halogenated	  pyrimidines	  have	  also	  been	  studied	  for	  many	  years.	   In	   the	  1950’s,	   Zamenhof,	  DeGiovani	   and	  Greer	   first	   demonstrated	  that	   BU	   replacement	   on	   the	   DNA	   of	   bacterial	   cells	  makes	   them	  more	   sensitive	   to	  ultraviolet	   radiation	   than	   bacterial	   cells	   without	   BU	   substitution	   [85,	   86].	   In	   the	  early	   1960s,	   Djordjevic	   and	   Szybalski	   observed	   an	   increase	   in	   the	   sensitivity	   of	  mammalian	   cells	   to	   both	   X-­‐ray	   and	   ultraviolet	   irradiation	   when	   the	   cells	   were	  pretreated	  with	  Bromodeoxyuridine	  (5-­‐	  bromo-­‐2’-­‐deoxyuridine,	  BrdU,	  BUdR)	  [87].	  The	  potential	  of	  using	  halogenated	  pyrimidines	  as	  clinical	  radiosensitizers	  was	  first	  proposed	  by	  Kaplan	  [88].	  Thymidine	  in	  the	  DNA	  can	  be	  substituted	  by	  halogenated	  pyrimidines	  such	  as	  bromo-­‐	  or	  ioso-­‐deoxyuridine	  (BrdU	  or	  IdU),	  thus	  enhance	  DNA	  damage	  and	  cell	  death	  induced	  by	  ionizing	  radiation	  or	  UV	  phorolysis.	  The	  ultrafast	  DET	  reaction	  between	   e!"#!   and	  halogenated	  pyrimidines	  was	  first	  observed	  by	  our	  group	   real-­‐timely	   using	   fs-­‐TRLS,	   revealing	   the	   meachanism:	   e!"#!   +   BrdU →BrdU∗! → Br!   +   dU ,	   which	   is	   similar	   to	   the	   electron	   transfer	   mechanism	   of	  cisplatin[89-­‐91].	   However,	   the	   ultrafast	   DET	   reaction	   between	   halogenated	  pyrimidines	   and	   e!"#! 	   are	   far	   less	   efficient	   than	   that	   between	   cisplatin	   and	   e!"#! ,	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because	   –NH2	   groups	   in	   cisplatin	   act	   as	   effective	   promoters	   for	   electron	   transfer	  reactions	  [92].	   	  	  
1.2.4 FMD-­‐Br-­‐DAB	  as	  a	  Potential	  Radiosensitizer	  	   The	   application	   of	   fs-­‐TRLS	   to	   chemical	   and	   biological	   systems	   spawned	   the	  fields	   of	   femtochemistry	   and	   femtobiology,	   and	   it	   also	   led	   to	   the	   development	   of	  
femtomedicine	  (FMD),	  which	  combines	  ultrafast	  laser	  spectroscopic	  techniques	  and	  biomedical	   sciences	   [93].	   The	   better	   understanding	   of	   reductive	   DNA-­‐damage	  mechanism	  and	  the	  molecular	  mechanism	  of	  cisplatin	  and	  halogenated	  pyrimidines	  as	   radiosensitizers,	   contributes	   to	   our	   discovery	   of	   a	   non-­‐platinum-­‐based	  radiosensitizing	  agent	  that	  can	  mimic	  the	  radiosensitizing	  effect	  of	  cisplatin	  but	  has	  less	   cytotoxicity	   than	   cisplatin.	   The	  new	   radiosensitizer	   contains	   an	   aromatic	   ring	  instead	  of	  platinum	  coordinating	  ion,	  and	  the	  aromatic	  ring	  couples	  two	  NH2	  groups	  as	  the	  electron	  transfer	  promoter	  and	  one	  bromine	  atom.	  The	  molecular	  formula	  of	  the	   agent	   is	   4-­‐bromo-­‐1,2-­‐diaminobenzene,	   which	   is	   denoted	   as	   FMD-­‐Br-­‐DAB	   or	  B(NH2)2Br	   hereinafter.	   The	   B(NH2)2Br	   is	   very	   effective	   in	   DET	   reactions	   with	  weakly-­‐bound	   electrons	   (e!"! ),	   which	   are	   rich	   in	   cancer	   cells	   [94].	   Also,	   the	   e!"#! 	  produced	   by	   radiolysis	   of	   water	   as	   a	   result	   of	   ionizing	   radiation	   is	   also	   a	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weekly-­‐bound	   electron	   that	   can	   react	  with	   B(NH2)2Br	   effectively.	   The	  mechanism	  can	  be	  described	  as:	  e!"#!   +   B NH! !Br → B NH! !Br ∗! → Br!   +   B NH! ! In	  this	  reaction,	   B NH! !Br ∗!	   is	  a	  transient	  vibrationally-­‐excited	  anion	  state,	  and	   the	   B NH! ! 	  is	   highly	   reactive	   that	   can	   lead	   to	   DNA	   strand	   breaks.	   The	  B(NH2)2Br	   is	   more	   efficient	   in	   DET	   reaction	   than	   cisplatin	   and	   halogenated	  pyrimidines	   but	   has	   much	   less	   cytotoxicity	   than	   cisplatin	   due	   to	   the	   absence	   of	  platinum.	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Chapter	  2.	  Cell	  Survival	  Study	  by	  MTT	  assay	  
	  	  
2.1	  Introduction	  
	   In	  order	  to	  test	  drug	  sensitivity	  and	  cytotoxicity,	  it	  is	  necessary	  to	  perform	  cell	  survival	  assays.	  MTT	  assay	  is	  one	  of	  the	  most	  common	  cell	  survival	  and	  proliferation	  assays.	   MTT	   (3-­‐(4,5-­‐dymethylthiazolyl-­‐2)-­‐2,5-­‐diphenyltetrazolium	   bromide),	   a	  water-­‐soluble	   yellow	   tetrazolium	   salt,	   is	   reduced	   to	   a	   water-­‐insoluble	   purple	  formazan	  in	  metabolically	  active	  cells	  by	  the	  action	  of	  mitochondrial	  dehydrogenase.	  The	   amount	   of	   formazan	   production	   in	   a	   given	   time	   is	   directly	   proportional	   to	  number	   of	   living	   cells	   because	   only	   living	   cells	   can	   actively	   cleave	   MTT.	   Using	   a	  solubilizing	   agent,	   for	   example	   dimethyl	   sulfoxide	   (DMSO)	   or	   sodium	   dodecyl	  sulfate	  (SDS),	   the	  purple	   formazan	  can	  be	  solubilized	  and	  quantified	  by	  measuring	  the	  absorbance	  with	  the	  help	  of	  a	  spectrophotometer	  [95-­‐97].	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2.2	  Experimental	  details	  
	  
Cell	  lines	  and	  culture	  conditions	  The	   cell	   line	  used	   in	   this	   research	   is	  MDA-­‐MB-­‐231,	   a	  metastatic	   human	  breast	  cancer	   cell	   line	  originally	   isolated	   from	  a	  patient	   in	  1973	   [98].	   It	   exhibits	   invasive	  properties	  when	  cultured	  in	  vitro	  and	  is	  widely	  used	  as	  a	  model	  for	  triple-­‐negative	  breast	  cancer.	  The	   MDA-­‐MB-­‐231	   cells	   were	   cultured	   with	   L-­‐15	   Medium	   (Leibovitz)	  supplemented	  with	  10%	   fetal	  bovine	   serum	  (FBS),	  100	  units/mL	  penicillin	  G,	   and	  100ug/mL	   streptomycin,	   and	   they	   were	   incubated	   at	   37	   ºC	   in	   a	   humidified	   air	  atmosphere	  without	  CO2.	  The	  MDA-­‐MB-­‐231	  cells	  and	  L-­‐15	  Medium	  were	  purchased	  from	   American	   Type	   Culture	   Collection.	   The	   FBS	   was	   purchased	   from	   Hyclone	  Laboratories.	   	  The	  cells	  were	  sub-­‐cultured	  every	  4	  days	  or	  when	  they	  were	  80-­‐90%	  confluent.	  To	   subculture	   the	   cells,	   they	   were	   washed	   with	   phosphate	   buffered	   saline	   (PBS)	  twice	   after	   removing	   the	   original	   culture	  medium,	   then	   an	   appropriate	   volume	   of	  0.25%	   trypsin-­‐0.53mM	   EDTA	   solution	  was	   added	   to	   the	   flask.	   After	   the	   cells	   had	  de-­‐attached	   and	   rounded	   up,	   a	   proper	   amount	   of	   complete	   growth	   medium	   was	  added	   to	   neutralize	   the	   trypsin.	   Then	   the	   cells	  were	   harvested	   by	   gently	  washing	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with	  the	  medium	  added.	  The	  cell-­‐medium	  solution	  was	  removed	  and	  centrifuged	  at	  700	   rpm.	   After	   centrifugation,	   the	   old	   medium	   was	   gently	   aspirated,	   and	   the	  completed	   medium	  was	   re-­‐added;	   the	   pellet	   of	   cells	   was	   re-­‐suspended	   by	   gentle	  pipetting.	  A	  proper	  amount	  of	  cell-­‐medium	  solution	  was	  transferred	  to	  a	  new	  T-­‐75	  flask	  to	  reach	  a	  sub-­‐cultivation	  ratio	  of	  1:2	  to	  1:4,	  and	  complete	  growth	  medium	  was	  added	  to	  a	  total	  of	  14mL.	  Then	  cell	  cultures	  were	  incubated	  at	  37	   ºC	  without	  CO2.	  	  
MTT	  assay	  A	  cell	  suspension	  was	  prepared	  and	  seeded	  in	  96-­‐well	  plates	  at	  5000	  cells/well	  and	   incubated	   at	   37ºC	   without	   CO2	   for	   24	   hours.	   Various	   concentrations	   of	  FMD-­‐Br-­‐DAB	  were	  added	   to	  each	  well.	  After	  24	  hours	  of	  drug	   treatment,	   the	   cells	  were	   irradiated	   with	   different	   doses	   of	   X-­‐ray	   using	   X-­‐ray	   irradiator	   IR225.	   The	  duration	  of	  irradiation	  was	  adjusted	  to	  reach	  the	  desired	  dose.	  The	  cells	  were	  then	  incubated	   for	   6	   days.	   After	   incubation,	   the	   cells	   were	   replaced	   with	   100ul	  serum-­‐free	   medium	   containing	   1mg/ml	   MTT	   and	   were	   incubated	   for	   a	   further	   4	  hours	  in	  the	  dark	  at	  37ºC	  without	  CO2.	  Next,	  100ul	  of	  10%	  SDS/0.01M	  HCl	  solution	  was	   added	   to	   each	  well	   as	   a	   solubilizing	   agent.	   After	   2-­‐4	   hours	   of	   incubation,	   the	  fraction	  of	   live	   cells	  was	  determined	  by	  measuring	   the	  absorbance	  at	  570nm	  by	  a	  spectrophotometer.	  The	  cell	  survival	  rate	  of	  untreated	  control	  cells	  is	  taken	  as	  100%,	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and	   since	   the	   number	   of	   live	   cells	   has	   a	   linear	   relationship	   with	   the	   absorbance	  value,	   the	   cell	   survival	   rate	   of	   the	   experimental	   group	   is	   calculated	   as	   the	  absorbance	   value	   of	   the	   experimental	   group	   divided	   by	   the	   absorbance	   of	   the	  untreated	  control	  group.	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2.3	  Results	  	   MDA-­‐MB-­‐231	  triple-­‐negative	  breast	  cancer	  cells	  were	  treated	  with	  0	  μM,	  10	  μM,	  20	  μM	  and	  60	  μM	  FMD-­‐Br-­‐DAB	  for	  24	  hours,	  followed	  by	  X-­‐ray	  irradiation	  at	  0	  Gy,	  4	  Gy,	  8	  Gy	  and	  16	  Gy.	  The	  cell	  survival	  fraction	  6	  days	  post-­‐irradiation	  was	  measured	  by	  MTT	  assay,	  and	  results	  are	  shown	  in	  Figure	  2.1.	  Normalized	  results	  are	  shown	  in	  Figure	  2.2.	   	  	  
	  
Figure	  2.1:	  Cell	  survival	  fraction	  for	  MDA-­‐MB-­‐231	  cells	  treated	  with	  0-­‐60	  μM	  of	  FMD-­‐Br-­‐DAB	  and	  0-­‐16	  Gy	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Figure	  2.2:	  Cell	  survival	  fraction	  for	  MDA-­‐MB-­‐231	  cells	  treated	  with	  0-­‐60	  μM	  of	  FMD-­‐Br-­‐DAB	  and	  0-­‐16	  Gy	  
of	  X-­‐ray	  irradiation.	  Cell	  survivals	  at	  different	  dose	  of	  X-­‐ray	  without	  FMD-­‐Br-­‐DAB	  treatment	  have	  all	  been	  
normalized	  to	  100%.	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2.4	  Discussions	  and	  Conclusions	  
	   The	   data	   plotted	   in	   Figure	   2.1	   show	   that	   when	   cells	   were	   treated	   with	  FMD-­‐Br-­‐DAB	  alone	  (no	  X-­‐ray	  irradiation),	   the	  cell	  survival	   fraction	  is	  around	  80%.	  Even	  at	  the	  highest	  concentration	  of	  FMD-­‐Br-­‐DAB,	  which	  is	  60	  μM,	  the	  cell	  survival	  fraction	  is	  75%,	  which	  indicates	  that	  FMD-­‐Br-­‐DAB	  only	  has	  little	  cytotoxicity	  when	  used	   alone.	   When	   cells	   were	   treated	   with	   4	   Gy	   of	   X-­‐ray	   irradiation	   and	   various	  concentrations	  of	  FMD-­‐Br-­‐DAB,	  the	  cell	  survival	  fraction	  reduces	  from	  93%	  to	  61%	  as	   the	   concentration	   of	   FMD-­‐Br-­‐DAB	   increases	   from	   0	   μM	   to	   60	   μM	   with	   a	  concentration	   dependent	   manner.	   When	   cells	   were	   treated	   with	   8	   Gy	   of	   X-­‐ray	  irradiation	   and	   various	   concentrations	   of	   FMD-­‐Br-­‐DAB,	   the	   cell	   survival	   fraction	  reduces	   from	  80%	   to	  53%	   in	   a	   concentration	  dependent	  manner.	   Similarly,	  when	  cells	   were	   treated	   with	   16	   Gy	   of	   X-­‐ray	   irradiation	   and	   various	   concentrations	   of	  FMD-­‐Br-­‐DAB,	   the	   cell	   survival	   fraction	   reduces	   from	   70%	   to	   45%	   as	   the	  concentration	  of	  FMD-­‐Br-­‐DAB	  increases	  from	  0	  μM	  to	  60	  μM.	  The	  cell	  survival	  fractions	  treated	  with	  different	  concentration	  of	  FMD-­‐Br-­‐DAB	  alone	   are	   normalized	   to	   100%	   and	   plotted	   in	   Figure	   2.2.	   This	   figure	   provides	  evidence	   of	   the	   synergistic	   effect	   between	   FMD-­‐Br-­‐DAB	   and	   radiation,	   which	   is	  induced	  by	  the	  radiosensitizing	  effect	  of	  FMD-­‐Br-­‐DAB.	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These	   MTT	   results	   reveal	   that	   FMD-­‐Br-­‐DAB	   treatment	   alone	   has	   limited	  cytotoxicity	  effects	  on	  MDA-­‐MB-­‐231	  cells	  up	  to	  the	  highest	  concentration	  of	  60	  μM,	  but	   cytotoxic	   effect	   increases,	   when	   FMD-­‐Br-­‐DAB	   is	   used	   in	   combination	   with	  radiation.	  The	  results	  also	  suggest	  the	  radiosensitizing	  effect	  of	  FMD-­‐Br-­‐DAB,	  which	  enhances	  cell	  killing	  synergistically	  with	  radiation.	  The	  promising	  MTT	  results	  opens	  up	   the	  possibility	  of	  using	  FMD-­‐Br-­‐DAB	  as	  a	  radiosensitizer	   to	   treat	   breast	   cancer	   and	   especially	   triple-­‐negative	   breast	   cancer,	  which	  cannot	  be	  treated	  with	  hormonal	  therapy	  and	  is	  generally	  more	  aggressive.	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Chapter	  3.	  Cell	  Survival	  Study	  by	  Clonogenic	  Assay	  
	  
3.1	  Introduction	  
	   Clonogenic	  assay	  measures	  cell	  survival	  and	  proliferation	  based	  on	  the	  ability	  of	  a	  single	  cell	  to	  reproduce	  into	  a	  colony	  consisting	  of	  at	  least	  50	  cells.	  These	  colonies	  can	   be	   visualized	  with	   naked	   eye	   and	   are	   countable.	   The	   ratio	   of	   colonies	   to	   the	  number	  of	   seeded	  cells	   indicates	   the	  capacity	  of	   cells	   to	   reproduce.	  A	  cell	   survival	  curve	  describes	  the	  relationship	  between	  the	  dose	  of	   the	  agent	  and	  the	   fraction	  of	  the	   cells	   that	   retain	   the	   capability	   to	   produce	   colonies.	   Unlike	   MTT	   assay,	   which	  distinguishes	  live	  and	  dead	  cells	  by	  metabolic	  function,	  clonogenic	  assay	  only	  takes	  into	  account	  cells	   that	  can	  divide	  “unlimitedly”.	  A	  cell	   that	  retains	   the	  ability	   to	  go	  through	   only	   one	   or	   two	  mitoses	   but	   cannot	   form	   a	   colony	   is	   considered	   dead	   in	  clonogenic	   assays	   [99,	   100].	   Although	   they	   are	   more	   time	   consuming	   than	   MTT	  assays	   and	   usually	   takes	   about	   2-­‐3	   weeks	   incubation	   time	   to	   form	   colonies,	  clonogenic	   assays	   are	   considered	   to	   be	   the	   optimal	   method	   to	   determine	   cell	  radiosensitivity	   and	   reproductive	   death	   after	   treatment	   with	   ionizing	   radiation	  [101].	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3.2	  Experimental	  details	  
	  Cells	  were	  obtained	  from	  sub-­‐cultured	  MDA-­‐MB-­‐231	  cell	   line	  by	  trypsinization,	  and	  the	  process	   is	  similar	   to	   the	  sub-­‐culture	  process	  described	   in	   the	   last	  chapter.	   	  When	  the	  cells	  started	  to	  detach,	  complete	  growth	  medium	  was	  added	  to	  neutralize	  trypsin.	  The	  cells	  were	  harvested	  by	  gently	  pipetting	  the	  cell-­‐medium	  solution.	  Then	  the	   solution	   was	   centrifuged	   at	   700	   rpm,	   and	   the	   supernatant,	   which	   contained	  medium	  and	  trypsin,	  was	  removed.	  A	  proper	  amount	  of	  complete	  growth	  medium	  was	   re-­‐added	   to	   the	   sediment,	   which	   contained	   the	   cells,	   and	   a	   single	   cell	  suspension	   was	   obtained	   by	   pipetting	   the	   solution.	   Then,	   cell	   concentration	   was	  counted	  using	  a	  Moxi	  Z	  automated	  cell	  counter.	  Desired	  seeding	  concentration	  can	  be	   obtained	   by	   diluting	   the	   cell	   suspension	   with	   a	   proper	   amount	   of	   complete	  growth	  medium,	  and	  the	  dilution	  can	  be	  used	  to	  seed	  cells	   in	  culture	  dishes.	  After	  seeding,	  the	  cells	  were	  incubated	  at	  37ºC	  without	  CO2	  until	  they	  had	  attached	  to	  the	  dishes.	   Various	   concentrations	   of	   compound	   D	  were	   added	   to	   each	   dish,	   and	   the	  cells	  were	   incubated	   for	   a	   further	   24	   hours	   at	   the	   same	   condition.	   After	   the	   drug	  treatment,	   the	   cells	   were	   irradiated	   with	   desired	   doses	   of	   X-­‐ray	   using	   X-­‐ray	  irradiator	   IR225.	   The	   dishes	  were	   then	   incubated	   until	   the	   cells	   in	   control	   group	  have	  formed	  sufficient	  large	  clones.	  It	  usually	  took	  about	  more	  than	  14	  days.	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The	   colonies	   were	   dyed	   with	   glutaraldehyde	   crystal	   violet	   mixture,	   which	  contains	  6%	  glutaraldehyde	  and	  0.5%	  crystal	  violet.	  The	  medium	  was	  removed	  by	  gentle	   aspiration,	   and	   the	   dishes	  were	   rinsed	   twice	  with	   PBS.	   After	   removing	   the	  PBS,	  an	  amount	  of	  3ml	  glutaraldehyde	  crystal	  violet	  was	  added	  to	  each	  dish.	  After	  30	  min,	  the	  glutaraldehyde	  crystal	  violet	  was	  removed,	  and	  the	  dishes	  were	  rinsed	  gently	  with	   tap	  water.	  When	   the	   dishes	   became	   dry,	   the	   number	   of	   colonies	  was	  counted	  by	  naked	  eye	  or	  microscope.	  The	  survival	  fraction	  of	  the	  untreated	  control	  group	  was	  set	  to	  100%,	  and	  the	  survival	  fraction	  of	  other	  groups	  was	  calculated	  by	  the	  number	  of	  colonies	  of	  the	  experimental	  group	  divided	  by	  the	  number	  of	  colonies	  of	  the	  untreated	  control	  group.	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3.3	  Results	  	   	  MDA-­‐MB-­‐231	  triple-­‐negative	  breast	  cancer	  cells	  were	  treated	  with	  0	  μM,	  10	  μM	  and	  20	  μM	  FMD-­‐Br-­‐DAB	   for	  24	  hours,	   followed	  by	  X-­‐ray	   irradiation	  at	  0	  Gy,	  2	  Gy,	  and	   4	   Gy.	   The	   cell	   survival	   rates	   20	   days	   post-­‐irradiation	   were	   measured	   by	  clonogenic	  assay,	  and	  results	  are	  shown	  in	  Figure	  3.1.	  	  
	  	  
Figure	  3.1:	  Cell	  survival	  rates	  for	  MDA-­‐MB-­‐231	  cells	  treated	  with	  0-­‐20	  μM	  FMD-­‐Br-­‐DAB	  and	  0-­‐4	  Gy	  X-­‐ray.	  
The	  sensitizer	  enhancement	  ratio	  (SER)	  at	  20%	  survival	  fraction	  in	  MDA-­‐MB-­‐231	  cells	  treated	  with	  20	  μM	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3.4	  Discussions	  and	  Conclusions	  
	   As	  shown	   in	  Figure	  3.1,	   the	   survival	   fractions	  at	  0	  Gy,	  2	  Gy,	   and	  4	  Gy	  without	  FMD-­‐Br-­‐DAB	   treatment	   are	   100%   ±   5.3%,	   59%   ±   3.5%	   and	   20%   ±   1.2%,	  respectively.	  For	  cells	  pretreated	  with	  10	  μM	  FMD-­‐Br-­‐DAB,	  the	  survival	  fractions	  at	  0	  Gy,	  2	  Gy,	   and	  4	  Gy	  are	  93%  ±  6.3%,	  47%  ±  1.0%	  and	  15%  ±  1.2%,	   respectively.	  For	  cells	  pretreated	  with	  20	  μM	  FMD-­‐Br-­‐DAB,	  the	  survival	  fraction	  at	  0	  Gy,	  2	  Gy,	  and	  4	  Gy	  are	  84%  ±  3.2%,	  35%  ±  1.3%	  and	  9%  ±  0.7%,	  respectively.	  As	   seen	   in	   Figure	   3.1,	   the	   X-­‐ray	   dose	   required	   to	   produce	   a	   50%	   cell	   killing	  effect	   (IC50)	   is	   between	   2	   Gy	   and	   4	   Gy,	   whereas	   when	   combined	   with	   24	   h	  pre-­‐incubation	   of	   20	  μM	  FMD-­‐Br-­‐DAB,	   the	   IC50	   of	   X-­‐ray	   is	   less	   than	  2	  Gy.	   Even	   at	  lower	   concentration	   (10	   μM)	   of	   FMD-­‐Br-­‐DAB,	   the	   IC50	   of	   X-­‐ray	   is	   less	   than	   2	   Gy.	  These	   results	   show	   that	   the	   IC50	   of	   X-­‐ray	   is	   significantly	   reduced	   when	   cells	   are	  pretreated	  with	  FMD-­‐Br-­‐DAB,	  and	  the	  higher	  the	  concentration	  of	  FMD-­‐Br-­‐DAB,	  the	  lower	  the	  IC50	  at	  specific	  dose	  of	  X-­‐ray.	   	  In	   the	   absence	   of	   X-­‐ray,	   the	   survival	   fraction	   is	   93%   ±  6.3%	   at	   10	   μM	  concentration	   of	   FMD-­‐Br-­‐DAB,	   and	   the	   survival	   fraction	   is	   84%	   ±  3.2%	   at	   the	  highest	  FMD-­‐Br-­‐DAB	  concentration	  of	  20	  μM.	  Our	  data	   indicates	  that	  FMD-­‐Br-­‐DAB	  alone	   has	   only	  minimal	   effects	   on	   cytotoxicity	   and	   clonogenic	   survival	   (long-­‐term	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cell	   survival).	  However,	   radiation-­‐induced	   cytotoxicity	   is	   significantly	   enhanced	  as	  the	   dose	   of	   FMD-­‐Br-­‐DAB	   increases.	   This	   enhancement	   provides	   evidence	   of	   the	  radiosensitizing	  effect	  of	  FMD-­‐Br-­‐DAB,	  and	  is	  also	  consistent	  with	  the	  results	  of	  the	  MTT	  assay.	  The	  clonogenic	  survival	  at	  20	  μM	  FMD-­‐Br-­‐DAB	  treatment	  combined	  with	  4	  Gy	  X-­‐ray	   irradiation	   is	  even	   less	   than	  10%,	  suggesting	  that	  FMD-­‐Br-­‐DAB	  has	   the	  potential	  to	  be	  an	  effective	  radiosensitizer.	   	  Also,	   the	   sensitizer	   enhancement	   ratio	   (SER)	   at	   20%	   cell	   survival	   is	   1.36,	  calculated	  by	  dividing	  the	  magnitude	  of	  X-­‐ray	  dose	  leading	  to	  a	  20%	  cell	  survival	  at	  20μM	   of	   FMD-­‐Br-­‐DAB	   with	   the	   magnitude	   of	   X-­‐ray	   dose	   leading	   to	   a	   20%	   cell	  survival	  without	  FMD-­‐Br-­‐DAB	  treatment.	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Chapter	  4.	  Gel	  Electrophoresis	  
	  
4.1	  Introduction	  	  Agarose	   gel	   electrophoresis	   is	   the	   most	   effective	   way	   of	   separating	   DNA	  fragments	  based	  on	  their	  size.	  DNA	  samples	  are	  loaded	  into	  pre-­‐cast	  wells	  in	  the	  gel,	  and	   the	   gel	   is	   placed	   in	   an	   electrophoresis	   chamber,	   which	   is	   connected	   to	   an	  electric	  power	  source.	  The	  electric	  field	  consists	  of	  a	  negative	  charge	  at	  one	  end	  and	  a	  positive	  charge	  at	  the	  other.	  Since	  DNA	  is	  negatively	  charged	  due	  to	  the	  phosphate	  groups	  in	  the	  backbone	  of	  DNA,	  when	  the	  electric	  current	  is	  applied,	  DNA	  fragments	  will	  migrate	   from	   the	   negatively	   charged	   electrode	   to	   the	   positively	   charged	   one.	  The	  gel	  prepared	  by	  agarose	  can	  form	  a	  solid	  but	  porous	  matrix,	  and	  the	  pore	  size	  of	  1%	  agarose	  gel	  ranges	  from	  200-­‐500nm	  [102].	  As	  DNA	  fragments	  move	  through	  the	  pores	  of	  the	  gel,	  they	  meet	  with	  resistance.	  Therefore,	  the	  movement	  of	  the	  DNA	  is	  affected	   by	   the	   conformation	   of	   the	   DNA;	   the	   larger	   pieces	   move	   more	   slowly	  through	  the	  gel,	  while	  the	  smaller	  pieces	  move	  faster.	  Several	  samples	  can	  be	  loaded	  into	  individual	  wells	  in	  the	  same	  gel,	  and	  DNA	  molecules	  of	  a	  similar	  size	  will	  pass	  through	  the	  gel	  at	  the	  similar	  speed	  and	  end	  up	  in	  the	  same	  band.	  The	  moving	  rate	  is	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related	   to	   the	   conformation	   and	   size	   of	   the	   DNA	   molecule.	   The	   larger	   the	   DNA	  molecule,	  the	  faster	  and	  the	  further	  it	  will	  migrate.	   	  The	   DNA	   sample	   used	   in	   this	   experiment	   was	   plasmid,	   purified	   from	   E.	   coli	  cultures	   using	   the	   GeneJET™ 	   Plasmid	   Miniprep	   Kit	   purchased	   from	   Thermo	  Scientific.	   A	   plasmid	   DNA	   purified	   from	   a	   bacterial	   cell	   will	   exist	   a	   naturally	  occurring	  supercoiled	  shape,	  which	  has	  extra	  twists	  between	  double	  helix	  strands,	  thus	   forming	   a	   compact	   conformation,	   and	   this	   compact	   conformation	  makes	   the	  plasmid	   run	   faster	   than	   damaged	   DNA	   [103].	   If	   supercoiled	   circular	   DNA	   is	   SSB	  (single	   strand	   break)	   damaged,	   its	   conformation	   changes	   to	   circular	   relaxed	  conformation	  nicked	  circular.	  The	  mass	  does	  not	  change,	  but	   the	  volume	  becomes	  larger,	   thus	   the	   moving	   rate	   and	   migration	   length	   of	   SSB	   DNA	   is	   smaller	   than	  undamaged	   supercoiled	   form.	   If	   supercoiled	   circular	   DNA	   is	   DSB	   (double	   strand	  break)	  damaged,	  its	  conformation	  changes	  to	  linear.	  Typically,	  the	  rate	  of	  linear	  DNA	  migration	  is	  slower	  than	  that	  of	  its	  supercoiled	  form,	  but	  faster	  than	  its	  circular	  form.	  Therefore,	   the	  moving	   rate	  and	  migration	   length	  of	  different	   conformations	  of	   the	  same	  DNA	  are	   in	   the	  order	  of:	   supersoiled	   (undamaged)	  >	   linear	   (DSB)	  >	   circular	  (SSB).	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4.2	  Experimental	  Details	  
	  
Preparing	  Plasmid	  DNA	   	  DNA	   samples	   used	   in	   this	   experiment	  were	   prepared	   by	   a	   GeneJET™	   Plasmid	  Miniprep	   Kit	   purchased	   from	   Thermo	   Scientific.	   The	   kit	   contains	   Resuspension	  Solution,	   Lysis	   Solution,	   Neutralization	   Solution,	  Wash	   Solution,	   RNase	   A,	   Elution	  Buffer,	  GeneJET	  Spin	  Columns,	  and	  Collection	  Tubes.	   	  	   A	  single	  colony	  of	  E.	  coli	  cultures	  was	  picked	  and	  incubated	  for	  14	  hours	  at	  37ºC	  while	  being	  shaken	  at	  200-­‐250	  rpm.	  After	  incubation,	  the	  E.	  coli	  cells	  were	  harvested	  by	  centrifugation	  at	  8000	  rpm	  for	  2	  minutes.	  All	  remaining	  medium	  was	  removed,	  and	   the	   pelleted	   cells	  were	   resuspended	   in	   250	   μL	   of	  Resuspension	   Solution.	   The	  cell	  suspension	  was	  transferred	  to	  a	  microcentrifuge	  tube,	  and	  250	  μL	  of	  the	  Lysis	  Solution	  was	  added	  and	  mixed	  well.	  Then,	  350	  μL	  of	  the	  Neutralization	  Solution	  was	  added	  and	  mixed	   immediately	  and	   thoroughly.	  The	  solution	  was	  centrifuged	   for	  5	  minutes	   to	   pellet	   cell	   debris	   and	   chromosomal	   DNA,	   and	   the	   supernatant	   was	  transferred	   to	   the	   GeneJET	   spin	   column	   by	   pipetting.	   The	   tube	   together	  with	   the	  spin	   column	   was	   centrifuged	   for	   a	   further	   1	   minute,	   and	   the	   flow-­‐through	   was	  discarded.	  Next,	  500	  μL	  of	  the	  Wash	  Solution,	  prepared	  by	  adding	  35	  mL	  of	  Ethanol	  to	   20	  mL	  of	   concentrated	  Wash	   Solution,	  was	   added	   to	   the	  GeneJET	   spin	   column.	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Then,	   the	   wash	   procedure	   was	   repeated	   and	   the	   column	   was	   transferred	   to	   a	  collection	   tube,	  which	  was	   then	  centrifuged	   for	  1	  minute	   to	  segregate	  and	  remove	  the	  remaining	  Wash	  Solution.	  The	  GeneJET	  spin	  column	  was	   then	   transferred	   to	  a	  1.5	   mL	   microcentrifuge	   tube,	   and	   50	   μL	   of	   the	   Elution	   Buffer	   was	   added	   to	   the	  center	   of	   the	   column	   membrane	   to	   wash	   the	   plasmid.	   Finally,	   the	   column	   was	  discarded	  and	  the	  purified	  plasmid	  DNA	  was	  stored	  at	  -­‐20ºC.	   	  	  
Preparing	  Agarose	  Gel	  The	  buffer	  solution	  used	   in	   this	  experiment	  was	  1×TAE	  diluted	  by	  adding	  40	  mL	  of	  10×TAE	  to	  360mL	  of	  pure	  water.	  Then,	  0.4	  g	  of	  agarose	  powder	  was	  added	  to	  40	  mL	  1×TAE,	  and	  the	  mixture	  was	  heated	  in	  a	  microwave	  until	  clear	  and	  uniform.	  When	  the	  flask	  was	  cooled	  to	  60ºC,	  4	  μL	  of	  Ethidium	  Bromide	  (EtBr)	  was	  added	  to	  the	   agarose-­‐TAE	   solution,	   which	   was	   then	   poured	   into	   an	   apparatus	   for	  solidificantion.	  Next,	  a	  comb	  was	  inserted	  to	  generate	  12	  wells.	  After	  50	  minutes,	  the	  solution	  was	   solidified	   to	   gel	   and	   the	   comb	   removed.	   The	   remaining	   1×TAE	  was	  added	  to	  the	  apparatus	  to	  cover	  the	  gel.	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Loading	  DNA	  Treatment	  Samples	  The	   concentration	  of	   purified	  plasmid	  DNA	  was	  100	  ug/mL,	   and	   this	   solution	  was	   used	   as	   DNA	   stock	   solution	   to	   prepare	   DNA	   tratmenet	   samples.	   Each	   DNA	  sample	  was	  prepared	  by	  mixing	  6	  μL	  various	  concentrations	  of	  FMD-­‐Br-­‐DAB	  to	  2	  μL	  of	  DNA	  stock	  solution,	  which	  contained	  0.2	  μg	  DNA,	  to	  a	   total	  volume	  of	  8	  μL.	  The	  DNA	  samples	  were	  then	  irradiated	  with	  different	  doses	  of	  X-­‐ray.	  Then,	  8	  μL	  of	  each	  sample	   was	   added	   to	   1.6	   μL	   of	   6×loading	   dye	   and	   mixed	   well	   to	   obtain	   a	   total	  volume	  of	  9.6	  μL	  of	  DNA-­‐dye	  solution.	  Then,	  8	  μL	  of	  each	  solution	  from	  last	  step	  was	  added	  to	  each	  well	  on	  the	  gel	  carefully.	  Power	  was	  turned	  on	  and	  running	  time	  was	  set	  as	  2	  hours.	  	   At	   the	  end	  of	  gel	  electrophoresis,	  power	  was	  turned	  off	  and	  gel	  was	   taken	  out	  carefully.	   The	   gel	   was	   placed	   on	   a	   UV	   light	   box	   and	   photos	   of	   the	   fluorescent	  EtBr-­‐stained	  DNA	  bands	  were	  taken.	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4.3	  Results	  
	  	   Electrophoresis	  of	  DNA	  samples	  treated	  with	  0	  μM,	  50	  μM,	  100	  μM,	  and	  200	  μM	  of	  FMD-­‐Br-­‐DAB	  followed	  by	  X-­‐ray	  irradiation	  at	  0	  Gy,	  50	  Gy	  and	  100	  Gy	  is	  shown	  in	  Figure	  4.1.	  The	  quantified	  amounts	  of	  SSBs	  and	  DSBs	  are	  given	  in	  Figure	  4.2	  and	  4.3,	  respectively.	   	  	  
	  
Figure	  4.1:	  Gel	  electrophoresis	  of	  DNA	  samples	  treated	  with	  0-­‐200	  μM	  FMD-­‐Br-­‐DAB	  combined	  with	  0-­‐100	  
Gy	  of	  X-­‐ray	  irradiation.	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Figure	  4.2:	  SSBs	  amount	  (with	  artificial	  unit)	  of	  DNA	  samples	  treated	  with	  0-­‐200	  μM	  FMD-­‐Br-­‐DAB	  
combined	  with	  0-­‐100	  Gy	  of	  X-­‐ray	  irradiation.	  	  
	  
Figure	  4.3:	  DSBs	  amount	  (with	  artificial	  unit)	  of	  DNA	  samples	  treated	  with	  0-­‐200	  μM	  FMD-­‐Br-­‐DAB	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The	  electrophoresis	  of	  DNA	  samples	  treated	  with	  0	  μM,	  50	  μM,	  100	  μM,	  and	  200	  μM	   of	   FMD-­‐Br-­‐DAB	   followed	   by	   X-­‐ray	   irradiation	   at	   0	   Gy,	   100	   Gy	   and	   200	   Gy	   is	  shown	   in	  Figure	  4.4.	  Quantified	  amounts	  of	  SSBs	  and	  DSBs	  are	  given	   in	  Figure	  4.5	  and	  4.6,	  respectively.	   	  	  
	  
Figure	  4.4:	  Gel	  electrophoresis	  of	  DNA	  samples	  treated	  with	  0-­‐200	  μM	  FMD-­‐Br-­‐DAB	  combined	  with	  0-­‐200	  
Gy	  of	  X-­‐ray	  irradiation.	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Figure	  4.5:	  SSBs	  amount	  (with	  artificial	  unit)	  of	  DNA	  samples	  treated	  with	  0-­‐200	  μM	  FMD-­‐Br-­‐DAB	  
combined	  with	  0-­‐200	  Gy	  of	  X-­‐ray	  irradiation.	  
	  	  
	  
Figure	  4.6:	  SSBs	  amount	  (with	  artificial	  unit)	  of	  DNA	  samples	  treated	  with	  0-­‐200	  μM	  FMD-­‐Br-­‐DAB	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The	  electrophoresis	  of	  DNA	  samples	   treated	  with	  0	  μM,	  250	  μM,	  500	  μM,	   and	  750	  μM	  of	  FMD-­‐Br-­‐DAB	  followed	  by	  X-­‐ray	  irradiation	  at	  0	  Gy,	  50	  Gy	  and	  100	  Gy	  is	  shown	  as	  Figure	  4.7.	  Quantified	   amount	  of	   SSBs	   and	  DSBs	   are	   given	   in	  Figure	  4.8	  and	  4.9,	  respectively.	   	  	  
	  
Figure	  4.7:	  Gel	  electrophoresis	  of	  DNA	  samples	  treated	  with	  0-­‐750	  μM	  FMD-­‐Br-­‐DAB	  combined	  with	  0-­‐100	  
Gy	  of	  X-­‐ray	  irradiation.	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Figure	  4.8:	  SSBs	  amount	  (with	  artificial	  unit)	  of	  DNA	  samples	  treated	  with	  0-­‐750	  μM	  FMD-­‐Br-­‐DAB	  
combined	  with	  0-­‐100	  Gy	  of	  X-­‐ray	  irradiation.	  	  
	  
Figure	  4.9:	  SSBs	  amount	  (with	  artificial	  unit)	  of	  DNA	  samples	  treated	  with	  0-­‐750	  μM	  FMD-­‐Br-­‐DAB	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4.4	  Discussions	  and	  Conclusions	  
	   In	   Figure	   4.1,	   it	   can	   be	   noticed	   that	   when	   the	   concentration	   of	   FMD-­‐Br-­‐DAB	  increases,	   the	   amount	   of	   SSBs	   increases	   significantly,	   especially	   when	   X-­‐ray	  irradiation	  is	  given	  together	  with	  FMD-­‐Br-­‐DAB.	  This	   finding	  can	  also	  be	  confirmed	  from	   Figure	   4.2.	   As	   Figure	   4.3	   indicates,	   DSBs	   tend	   to	   increase	   when	   the	  concentration	  of	  FMD-­‐Br-­‐DAB	  increases.	  When	   X-­‐ray	   doses	   increase	   to	   100	   Gy	   and	   200	   Gy,	   SSBs	   still	   increases	   as	   the	  concentration	   of	   FMD-­‐Br-­‐DAB	   increases,	   as	   is	   shown	   in	   both	   Figure	   4.4	   and	   4.5.	  DSBs	   also	   show	   an	   upward	   tendency	   when	   the	   concentration	   of	   FMD-­‐Br-­‐DAB	  increases,	  even	  though	  one	  inflection	  point	  is	  shown	  at	  200	  μM	  100	  Gy	  in	  Figure	  4.6.	   	  When	  the	  concentration	  of	  FMD-­‐Br-­‐DAB	  increases	  to	  250	  μM,	  500	  μM	  and	  750	  μM,	  as	  shown	  in	  Figure	  4.7,	  the	  amount	  of	  SSBs	  increases	  accordingly,	  as	  shown	  in	  Figure	   4.8.	   Enhancement	   of	   DSBs	   as	   a	   result	   of	   concentration	   increase	   is	   also	  observed	  in	  Figure	  4.9.	  Therefore,	  it	  can	  be	  concluded	  that	  FMD-­‐Br-­‐DAB	  can	  enhance	  SSB	  DNA	  damages,	  especially	  when	  it	  is	  combine	  with	  X-­‐ray	  irradiation.	  The	  amount	  of	  DSBs	  also	  has	  an	  upward	  tendency	  when	  the	  concentration	  of	  FMD-­‐Br-­‐DAB	  increases,	  but	  this	  trend	  is	  not	  as	  significant	  as	  that	  of	  SSBs.	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Chapter	  5.	  Flow	  Cytometry	  of	  Apoptotic	  Cell	  Death	  
	  
5.1	  Introduction	  	  	  Apoptotic	  cells	  are	  morphologically	  and	  biochemically	  different	  from	  live	  cells	  or	  necrotic	   cells.	   For	   apoptotic	   cells,	   nucleases	   are	   activated	   and	   the	   nuclear	   DNA	   is	  degraded	  into	  fragments	  with	  lengths	  of	  approximately	  200	  base	  pairs,	  and	  the	  DNA	  break	  sites	  expose	  a	  large	  number	  of	  3’-­‐hydroxyl	  ends.	  The	  hydroxyl	  groups	  can	  be	  used	  as	  starting	  points	  for	  terminal	  deoxynucleotidyl	  transferase	  to	  add	  nucleotides	  (or	   analogs	   of	   nucleotides).	   For	   example,	   the	   5-­‐bromo-­‐2’-­‐deoxyuridine	  5’-­‐tri-­‐phosphate	  (BrdUTP),	  a	  deoxythymidine	  analog	  can	  be	  added	  to	  label	  the	  break	  sites.	  The	  incorporated	  BrdU	  can	  be	  detected	  by	  a	  fluorescent	  dye	  conjugated	  with	  anti-­‐BrdU	  antibody.	  [107-­‐110]	  The	   APO-­‐BrdU™	   TUNEL	   Assay	   Kit,	   purchased	   from	   Invitrogen,	   was	   used	   to	  detect	   the	  DNA	   fragmentation	   of	   apoptotic	   cells.	   An	  Alexa	   Fluor®	   488	  dye-­‐labeled	  anti-­‐BrdU	  antibody	  was	  used	  to	  detect	   the	  BrdU	  incorporation	  at	  DNA	  break	  sites.	  Propidium	  iodide	  was	  also	  included	  to	  determine	  the	  total	  cellular	  DNA	  content.	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5.2	  Experimental	  details	  
	  
Cell	  Preparation	  and	  Fixation	  Cells	   were	   seeded	   in	   fourteen	   100mm	   dishes,	   with	   106	   cells	   per	   dish,	   and	  incubated	   at	   37ºC	  without	   CO2	  for	   12	   hours.	   Nine	   of	   the	   dishes	  were	   used	   as	   the	  experimental	  group,	  two	  were	  used	  as	  the	  negative	  controls,	  and	  three	  were	  used	  as	  positive	   controls.	   After	   incubation,	   various	   concentrations	   of	   FMD-­‐Br-­‐DAB	   were	  added	  to	  the	  corresponding	  dishes	  from	  the	  experimental	  group.	  After	  12	  hours	  of	  incubation,	   the	   samples	   from	   the	   experimental	   group	   were	   exposed	   to	   X-­‐ray	  irradiation	  at	  appropriate	  doses.	  For	  the	  negative	  control	  group,	  no	  drug	  treatment	  or	  X-­‐ray	   irradiation	  was	  applied.	  For	  the	  positive	  control	  group,	  cells	  were	  treated	  with	   200	   μM	   H2O2	   for	   18	   hours	   before	   harvesting.	   After	   another	   12	   hours	   of	  incubation,	   the	   cells	   were	   harvested	   by	   the	   procedure	   described	   in	   the	   previous	  chapter,	   and	   the	   cells	   from	   each	   sample	   were	   suspended	   in	   a	   separate	   0.5	   mL	  phosphate-­‐buffered	  saline	  (PBS)	  solution.	  Then,	  4mL	  of	  1%	  paraformaldehyde	  was	  added	  to	  fix	  the	  cells,	  and	  the	  cells	  were	  centrifuged	  at	  300×g	  and	  the	  supernatant	  was	   discarded.	   Next,	   the	   cells	   were	  washed	   twice	   by	   adding	   4.5	  mL	   of	   PBS,	   then	  centrifuged.	  After	  that,	  0.5	  mL	  of	  PBS	  was	  added	  and	  the	  cells	  were	  transferred	  to	  4	  mL	  of	  70%	   ice-­‐cold	   ethanol.	  Then	   the	   cells	  were	   stored	  at	   -­‐20ºC.	   For	   the	  positive	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control	   group,	   no	   drug	   treatment	   or	   X-­‐ray	   irradiation	  was	   applied	   but	   cells	  were	  treated	  with	  200	  μM	  H2O2	  for	  18	  hours	  before	  harvesting.	   	  	  
Detection	  of	  apoptosis	  The	  cells	  from	  each	  tube	  were	  re-­‐suspended	  in	  1	  mL	  of	  wash	  buffer	  provided	  in	  the	   kit	   and	   then	   centrifuged	   for	   5	  minutes	   at	   300×g,	   and	   the	   supernatants	  were	  removed	   by	   aspiration.	   The	   above	   operation	   was	   repeated	   once,	   and	   50	   μL	   of	  DNA-­‐labeling	   solution	   was	   added	   to	   each	   tube.	   The	   DNA-­‐labeling	   solution	   was	  prepared	  by	  mixing	  150	  μL	  of	  reaction	  buffer,	  11.25	  μL	  of	  TdT	  enzyme,	  and	  120	  μL	  of	  BrdUTP	  and	  468.75	  μL	  of	  deionized	  water.	  The	  cells	  were	  then	  incubated	  for	  60	  minutes	   at	   37ºC	   and	  were	   shaken	   every	   15	  minutes	   to	   keep	   them	   in	   suspension.	  After	  incubation,	  1.0	  mL	  of	  rinse	  buffer	  was	  added	  to	  each	  tube	  and	  the	  cells	  were	  pelleted	  by	   centrifugation.	  Then	  each	   cell	   pellet	  was	   re-­‐suspended	  with	  100	  μL	  of	  antibody	   solution,	   which	   was	   prepared	   by	  mixing	   75	   μL	   of	   the	   Alexa	   Fluor®	   488	  dye-­‐labeled	  anti-­‐BrdU	  antibody	  with	  1.43	  mL	  of	  rinse	  buffer	  provided	  from	  the	  kit,	  and	   the	   cells	   were	   incubated	   for	   30	   minutes	   at	   room	   temperature	   without	   light.	  Then,	  0.5	  mL	  of	   the	  propidium	   iodide/RNase	  A	   staining	  buffer	  was	  added	   to	   each	  sample,	   and	   the	   cells	   were	   incubated	   for	   an	   additional	   30	  minutes	   without	   light.	  After	  incubation,	  the	  samples	  were	  analyzed	  by	  flow	  cytometry.	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5.3	  Results	  	  	   The	   results	   of	   APO-­‐BrdU™	   TUNEL	   Assay	   for	   MDA-­‐MB-­‐231	   cells,	   without	   any	  treatment,	  are	  shown	  as	  pseudocolor	  plots	  in	  Figure	  5.1.	  A	  pseudocolor	  plot	  is	  a	  type	  of	  bivariate	  density	  plot	  that	  displays	  the	  number	  of	  events	  by	  colored	  pixels.	  Blue	  and	   green	   areas	   represent	   low	   population	   density;	   yellow	   areas	   correspond	   to	  mid-­‐range	  cell	  density;	  red	  and	  orange	  areas	  represent	  high	  cell	  density.	  The	  cells	  to	  the	   right	   of	   the	   vertical	   line	   represent	   BrdU	   positive	   cells,	   which	   are	   cells	  undergoing	   apoptosis.	   The	   cells	   to	   the	   left	   of	   the	   vertical	   line	   represent	   BrdU	  negative	  cells,	  which	  are	  non-­‐apoptosis	  cells.	  Therefore,	  the	  amount	  of	  Q1	  represents	  the	  percentage	  of	  apoptotic	  cells.	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Figure	  5.1:	  Bivariate	  density	  plot	  of	  APO-­‐BrdU™	  TUNEL	  Assay	  for	  MDA-­‐MB-­‐231	  control	  cells	  without	  any	  
treatment.	  Blue	  and	  green	  areas	  correspond	  to	  lower	  cell	  density;	  yellow	  to	  mid-­‐range	  cell	  density;	  red	  
and	  orange	  to	  high	  cell	  density.	  The	  cells	  to	  the	  right	  of	  the	  vertical	  line	  are	  BrdU	  positive	  (apoptotic).	  
Value	  of	  Q2	  represents	  percentage	  of	  apoptotic	  cells.	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Results	  of	  APO-­‐BrdU™	  TUNEL	  Assay	  for	  MDA-­‐MB-­‐231	  cells,	  treated	  with	  20μM	  FMD-­‐Br-­‐DAB	  for	  24	  hours	  without	  any	  X-­‐ray	  irradiation,	  are	  shown	  as	  pseudocolor	  plots	  in	  Figure	  5.2.	   	   	  
	  
Figure	  5.2:	  Bivariate	  density	  plot	  of	  APO-­‐BrdU™	  TUNEL	  Assay	  for	  MDA-­‐MB-­‐231	  cells	  treated	  with	  20μM	  
FMD-­‐Br-­‐DAB	  without	  any	  X-­‐ray	  irradiation.	  Blue	  and	  green	  correspond	  to	  areas	  of	  lower	  cell	  density,	  
yellow	  area	  represents	  mid-­‐range	  cell	  density,	  and	  red	  and	  orange	  are	  areas	  of	  high	  cell	  density.	  The	  cells	  
to	  the	  right	  of	  the	  vertical	  line	  are	  BrdU	  positive	  (apoptotic).	  Value	  of	  Q2	  represents	  percentage	  of	  
apoptotic	  cells.	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Results	   of	   APO-­‐BrdU™	   TUNEL	   Assay	   for	  MDA-­‐MB-­‐231	   cells,	   treated	  with	   2Gy	  X-­‐ray	   irradiation	  without	   any	   drug	   treatment,	   are	   shown	   as	   pseudocolor	   plots	   in	  Figure	  5.3.	   	   	  
	  
Figure	  5.3:	  Bivariate	  density	  plot	  of	  APO-­‐BrdU™	  TUNEL	  Assay	  for	  MDA-­‐MB-­‐231	  cells	  treated	  with	  2Gy	  
X-­‐ray	  irradiation	  without	  any	  drug	  treatment.	  Blue	  and	  green	  correspond	  to	  areas	  of	  lower	  cell	  density,	  
yellow	  area	  represents	  mid-­‐range	  cell	  density,	  and	  red	  and	  orange	  are	  areas	  of	  high	  cell	  density.	  The	  cells	  
to	  the	  right	  of	  the	  vertical	  line	  are	  BrdU	  positive	  (apoptotic).	  Value	  of	  Q2	  represents	  percentage	  of	  
apoptotic	  cells.	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Results	  of	  APO-­‐BrdU™	  TUNEL	  Assay	  for	  MDA-­‐MB-­‐231	  cells,	  treated	  with	  20μM	  FMD-­‐Br-­‐DAB	  followed	  by	  2Gy	  X-­‐ray	  irradiation,	  are	  shown	  as	  pseudocolor	  plots	   in	  Figure	  5.4.	   	   	  
	  
Figure	  5.4:	  Bivariate	  density	  plot	  of	  APO-­‐BrdU™	  TUNEL	  Assay	  for	  MDA-­‐MB-­‐231	  cells	  treated	  with	  20μM	  
FMD-­‐Br-­‐DAB	  followed	  by	  2Gy	  X-­‐ray	  irradiation.	  Blue	  and	  green	  correspond	  to	  areas	  of	  lower	  cell	  density,	  
yellow	  area	  represents	  mid-­‐range	  cell	  density,	  and	  red	  and	  orange	  are	  areas	  of	  high	  cell	  density.	  The	  cells	  
in	  the	  right	  side	  of	  the	  vertical	  line	  are	  BrdU	  positive	  cells	  (apoptotic	  cells).	  The	  cells	  to	  the	  right	  of	  the	  
vertical	  line	  are	  BrdU	  positive	  (apoptotic).	  Value	  of	  Q2	  represents	  percentage	  of	  apoptotic	  cells.	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5.4	  Discussions	  and	  Conclusions	  	   As	   shown	   in	   Figure	   5.1,	   1.46%	   of	   untreated	   MDA-­‐MB-­‐231	   cells	   undergo	  apoptosis	  and	  exhibit	  DNA	  fragmentation.	  Figure	  5.2	  shows	  that	  when	  MDA-­‐MB-­‐231	  cells	   are	   treated	  with	   20	   μM	  FMD-­‐Br-­‐DAB	   alone,	   only	   1.35%	  of	   the	   cells	   undergo	  early	   apoptosis	   and	   exhibit	   DNA	   fragmentation.	   Remarkably,	   the	   percentage	   of	  apoptotic	  cells	  from	  the	  FMD-­‐Br-­‐DAB	  treatment	  group	  is	  close	  to	  the	  percentage	  of	  apoptotic	  cells	  from	  the	  control	  group,	  and	  the	  percentage	  is	  even	  slightly	  lower	  that	  that	  of	  control	  group.	  These	  results	  reveal	  that	  FMD-­‐Br-­‐DAB	  treatment	  alone	  at	  the	  concentration	  of	  20μM	  does	  not	  induce	  apoptosis.	  In	  Figure	  5.3,	  when	  MDA-­‐MB-­‐231	   cells	   are	   treated	  with	  2	  Gy	  X-­‐ray	   irradiation	  alone,	  4.19%	  cells	  are	  apoptotic	  and	  exhibit	  DNA	  fragmentation.	  As	  shown	  in	  Figure	  5.4,	  when	  MDA-­‐MB-­‐231	  cells	  are	  treated	  with	  20	  μM	  FMD-­‐Br-­‐DAB	  followed	  by	  2	  Gy	  X-­‐ray	  irradiation,	  9.87%	  cells	  are	  apoptotic	  and	  exhibit	  DNA	  fragmentation.	  It	  can	  be	  seen	  from	  these	  results	  that	  when	  there	  is	  2	  Gy	  of	  X-­‐ray	  irradiation,	  the	  percentage	  of	   apoptotic	   cells	   is	   significantly	   enhanced	   (from	  4.19%	   to	   9.87%)	  when	   cells	   are	  pretreated	  with	  FMD-­‐Br-­‐DAB.	   	  In	   contrast	   to	   the	   results	   in	  Figure	  5.1	   and	  Figure	  5.2,	   in	  which	   the	   amount	  of	  apoptotic	   cells	  does	  not	   increase	  when	  cells	  were	  pretreated	  with	  FMD-­‐Br-­‐DAB	   in	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the	   absence	   of	   X-­‐ray,	   the	   results	   in	   Figure	   5.3	   and	   Figure	   5.4	   show	   significant	  enhancement	  of	   the	  amount	  of	   apoptotic	   cells.	  These	   findings	  provide	  evidence	  of	  the	   synergistic	   effect	   between	   FMD-­‐Br-­‐DAB	   and	   radiation,	   attributed	   to	   the	  radiosensitizing	  effect	  of	  FMD-­‐Br-­‐DAB.	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Chapter	  6.	  Conclusions	  
This	   study	   shows	   the	   radiosensitizing	   effect	   of	   a	   newly	   discovered	  non-­‐platinum-­‐based	   regimen,	   FMD-­‐Br-­‐DAB,	   used	   as	   a	   radiosensitizer	   for	  radiotherapy	  of	  breast	  cancer.	  In	  Chapters	  2	  and	  3,	  MTT	  assays	  and	  clonogenic	  assays	  have	  been	  conducted	  to	  evaluate	   the	   cytotoxicity	   and	   radiosensitizing	   effects	   of	   FMD-­‐Br-­‐DAB.	  Both	   results	  have	   shown	   that	   FMD-­‐Br-­‐DAB	   treatment	   alone	   has	   certain	   cytotoxicity	   effects	   on	  MDA-­‐MB-­‐231	   triple-­‐negative	   breast	   cancer	   cells.	   When	   FMD-­‐Br-­‐DAB	   is	   used	   in	  combination	  with	  radiation,	  cytotoxic	  effect	  appears	  and	  increases	  as	  concentration	  of	   FMD-­‐Br-­‐DAB	   increases.	   Both	   MTT	   assays	   and	   clonogenic	   assays	   open	   up	   the	  possibility	  of	  using	  FMD-­‐Br-­‐DAB	  as	  a	  radiosensitizer.	   	  In	   Chapters	   4,	   gel	   electrophoresis	   has	   been	   done	   to	   confirm	   whether	   the	  radiosensitizing	  effect	  of	  FMD-­‐Br-­‐DAB	   is	  due	   to	   the	  enhancement	  of	  DNA	  damage.	  Plasmid	  DNA	  has	  been	  treated	  with	  FMD-­‐Br-­‐DAB	  and	  radiation,	  and	  the	  results	  have	  shown	   that	  DNA	  damage	   is	   significantly	   increased	  when	  DNA	   is	   treated	  with	  both	  FMD-­‐Br-­‐DAB	   and	   X-­‐ray	   irradiation.	   These	   results	   are	   consistent	   with	   results	  obtained	   in	   previous	   chapters	   and	   directly	   prove	   that	   FMD-­‐Br-­‐DAB	   can	   enhance	  DNA	  damage	  when	  combined	  with	  radiation.	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In	  Chapters	  5,	   apoptotic	   cell	  death	   is	  detected	  and	   the	  percentage	  of	   apoptotic	  cells	   is	   measured	   by	   flow	   cytometry.	   The	   results	   are	   consistent	   with	   previous	  chapters,	  in	  which	  synergistic	  effects	  are	  observed	  between	  FMD-­‐Br-­‐DAB	  and	  X-­‐ray,	  and	  no	  apoptosis	  is	  induced	  by	  FMD-­‐Br-­‐DAB	  alone.	  	   In	   summary,	   this	   work	   confirms	   the	   radiosensitizing	   effect	   of	   a	   newly	  discovered	  non-­‐platinum-­‐based	  agent	   that	   can	  effectively	  enhance	   radiosensitivity	  of	  MDA-­‐MB-­‐231	  cells	  and	  enhance	  DNA	  damage	  in	  a	  dose-­‐dependent	  manner	  when	  combined	  with	  radiation.	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